The	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
,	O
but	O
not	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
.	O

Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	B-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation-related	O
genes	O
.	O

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	B-protein
in	O
induction	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
through	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
Ar-5	I-cell_line
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
isozymes	I-protein
of	O
PKC	B-protein
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
.	O

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
activity	O
in	O
Ar-5	B-cell_line
cells	I-cell_line
transfected	O
with	O
a	O
plasmid	B-DNA
containing	O
the	O
IL-2	B-DNA
promoter	I-DNA
linked	O
to	O
this	O
reporter	B-DNA
gene	I-DNA
.	O

The	O
IL-2	B-DNA
promoter	I-DNA
contains	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
factors	I-protein
including	O
NFAT-1	B-protein
,	O
Oct	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
AP-1	B-protein
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	B-protein
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	B-DNA
and	I-DNA
Oct	I-DNA
sites	I-DNA
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP-1	B-DNA
site	I-DNA
located	O
at	O
-150	B-DNA
bp	I-DNA
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
appearance	O
of	O
an	O
inducible	B-protein
nuclear	I-protein
factor	I-protein
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	B-protein
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c-fos	O
and	O
c-jun	O
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
minimally	B-cell_line
stimulated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B-protein
responsiveness	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

The	NULL
AP-1	NULL
Site	NULL
at	NULL
-150	NULL
bp	NULL
,	NULL
but	NULL
Not	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
Site	NULL
,	NULL
Is	NULL
Likely	NULL
to	NULL
Represent	NULL
the	NULL
Major	NULL
Target	NULL
of	NULL
Protein	NULL
Kinase	NULL
C	NULL
in	NULL
the	NULL
Interleukin	NULL
2	NULL
Promoter	NULL
By	NULL
Jugnu	NULL
Jain	NULL
,	NULL
``	NULL
Viia	NULL
E.	NULL
Valge-Archer	NULL
,	NULL
``	NULL
f	NULL
Anthony	NULL
J.	NULL
Sinskey	NULL
,	NULL
t	NULL
and	NULL
Anjana	NULL
Rao*	NULL
From	NULL
the	NULL
*Division	NULL
of	NULL
Tumor	NULL
Virology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
;	NULL
and	NULL
the	NULL
tDepartment	NULL
of	NULL
Biology	NULL
,	NULL
Massachusetts	NULL
Institute	NULL
of	NULL
Technology	NULL
,	NULL
Cambridge	NULL
,	NULL
Massachusetts	NULL
02139	NULL
Summary	NULL
Stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
antigen	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
several	NULL
kinases	NULL
,	NULL
including	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
,	NULL
that	NULL
may	NULL
mediate	NULL
the	NULL
later	NULL
induction	NULL
of	NULL
activation-related	NULL
genes	NULL
.	NULL

We	NULL
have	NULL
examined	NULL
the	NULL
potential	NULL
role	NULL
of	NULL
PKC	NULL
in	NULL
induction	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
in	NULL
T	NULL
cells	NULL
stimulated	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor/CD3	NULL
complex	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
prolonged	NULL
treatment	NULL
of	NULL
the	NULL
untransformed	NULL
T	NULL
cell	NULL
clone	NULL
Ar-5	NULL
with	NULL
phorbol	NULL
esters	NULL
results	NULL
in	NULL
downmodulation	NULL
of	NULL
the	NULL
a	NULL
and	NULL
isozymes	NULL
of	NULL
PKC	NULL
,	NULL
and	NULL
abrogates	NULL
induction	NULL
of	NULL
II-2	NULL
mRNA	NULL
and	NULL
protein	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
phorbol	NULL
ester	NULL
treatment	NULL
also	NULL
abolishes	NULL
induction	NULL
of	NULL
chloramphenicol	NULL
acetyltransferase	NULL
activity	NULL
in	NULL
Ar-5	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
IL-2	NULL
promoter	NULL
linked	NULL
to	NULL
this	NULL
reporter	NULL
gene	NULL
.	NULL

The	NULL
IL-2	NULL
promoter	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
nuclear	NULL
factors	NULL
including	NULL
NFAT-1	NULL
,	NULL
Oct	NULL
,	NULL
NF-B	NULL
,	NULL
and	NULL
AP-1	NULL
,	NULL
which	NULL
are	NULL
all	NULL
potentially	NULL
sensitive	NULL
to	NULL
activation	NULL
of	NULL
PKC	NULL
.	NULL

We	NULL
show	NULL
that	NULL
induction	NULL
of	NULL
a	NULL
trimer	NULL
of	NULL
the	NULL
NFAT	NULL
and	NULL
Oct	NULL
sites	NULL
is	NULL
not	NULL
sensitive	NULL
to	NULL
phorbol	NULL
ester	NULL
treatment	NULL
,	NULL
and	NULL
that	NULL
mutations	NULL
in	NULL
the	NULL
NF-KB	NULL
site	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
inducibility	NULL
of	NULL
the	NULL
II	NULL
>	NULL
2	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mutations	NULL
in	NULL
the	NULL
AP-1	NULL
site	NULL
located	NULL
at	NULL
-150	NULL
bp	NULL
almost	NULL
completely	NULL
abrogate	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
and	NULL
appearance	NULL
of	NULL
an	NULL
inducible	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
is	NULL
sensitive	NULL
to	NULL
PKC	NULL
depletion	NULL
.	NULL

Moreover	NULL
,	NULL
cotransfections	NULL
with	NULL
c-fos	NULL
and	NULL
c-jun	NULL
expression	NULL
plasmids	NULL
markedly	NULL
enhance	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
minimally	NULL
stimulated	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
AP-1	NULL
site	NULL
at	NULL
-150	NULL
bp	NULL
represents	NULL
a	NULL
major	NULL
,	NULL
if	NULL
not	NULL
the	NULL
only	NULL
,	NULL
site	NULL
of	NULL
PKC	NULL
responsiveness	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
by	NULL
antigen	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
serine/threonine	NULL
and	NULL
tyrosine	NULL
kinases	NULL
,	NULL
and	NULL
later	NULL
in	NULL
induction	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
activation-associated	NULL
genes	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
1-3	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
best	NULL
characterized	NULL
of	NULL
the	NULL
kinases	NULL
is	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
,	NULL
a	NULL
family	NULL
of	NULL
phospholipid-dependent	NULL
serine/threonine	NULL
kinases	NULL
that	NULL
are	NULL
activated	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
increased	NULL
phosphatidylinositol	NULL
turnover	NULL
in	NULL
stimulated	NULL
T	NULL
cells	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Gene	NULL
induction	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
is	NULL
at	NULL
least	NULL
partly	NULL
mediated	NULL
by	NULL
PKC	NULL
,	NULL
since	NULL
phorbol	NULL
esters	NULL
(	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
calcium	NULL
ionophores	NULL
)	NULL
can	NULL
activate	NULL
PKC	NULL
and	NULL
gene	NULL
expression	NULL
in	NULL
parallel	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
3	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
phorbol	NULL
esters	NULL
induce	NULL
a	NULL
variety	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
are	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
phorbol	NULL
ester-inducible	NULL
genes	NULL
.	NULL

Among	NULL
these	NULL
is	NULL
the	NULL
AP-1	NULL
(	NULL
Fos/Jun	NULL
)	NULL
transcription	NULL
factor	NULL
,	NULL
which	NULL
is	NULL
newly	NULL
synthesized	NULL
as	NULL
well	NULL
as	NULL
posttranslationally	NULL
modified	NULL
in	NULL
phorbol	NULL
ester-stimu-	NULL
1	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
hGH	NULL
,	NULL
human	NULL
growth	NULL
hormone	NULL
.	NULL

lated	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
,	NULL
and	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
,	NULL
which	NULL
is	NULL
released	NULL
from	NULL
a	NULL
preexisting	NULL
cytosolic	NULL
complex	NULL
with	NULL
an	NULL
in-hibitory	NULL
protein	NULL
upon	NULL
phorbol	NULL
ester	NULL
treatment	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
gene	NULL
for	NULL
the	NULL
lymphokine	NULL
IL-2	NULL
,	NULL
a	NULL
growth	NULL
factor	NULL
for	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
,	NULL
is	NULL
induced	NULL
within	NULL
1-6	NULL
h	NULL
after	NULL
TCR	NULL
stimulation	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
,	NULL
and	NULL
represents	NULL
a	NULL
good	NULL
model	NULL
system	NULL
for	NULL
investigating	NULL
the	NULL
relation	NULL
between	NULL
PKC	NULL
activation	NULL
and	NULL
lymphokine	NULL
gene	NULL
induction	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
sites	NULL
relevant	NULL
for	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
have	NULL
been	NULL
exhaustively	NULL
mapped	NULL
.	NULL

Both	NULL
constitutive	NULL
(	NULL
Oct	NULL
)	NULL
and	NULL
inducible	NULL
(	NULL
NFAT-1	NULL
,	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
CD28RC	NULL
)	NULL
DNA	NULL
binding	NULL
factors	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
induction	NULL
(	NULL
11-19	NULL
)	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
inducible	NULL
factors	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
phorbol	NULL
esters	NULL
and/or	NULL
calcium	NULL
ionophores	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
suggesting	NULL
the	NULL
potential	NULL
involvement	NULL
of	NULL
PKC	NULL
and/or	NULL
calcium-dependent	NULL
kinases	NULL
.	NULL

Moreover	NULL
the	NULL
induction	NULL
of	NULL
c-Fos	NULL
,	NULL
a	NULL
component	NULL
of	NULL
the	NULL
AP-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
7	NULL
)	NULL
,	NULL
is	NULL
PKC	NULL
dependent	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

By	NULL
itself	NULL
,	NULL
the	NULL
use	NULL
of	NULL
phorbol	NULL
esters	NULL
has	NULL
not	NULL
been	NULL
sufficient	NULL
to	NULL
prove	NULL
the	NULL
involvement	NULL
of	NULL
PKC	NULL
,	NULL
since	NULL
the	NULL
activity	NULL
of	NULL
several	NULL
other	NULL
kinases	NULL
and	NULL
enzymatic	NULL
processes	NULL
can	NULL
be	NULL
secondarily	NULL
regu-	NULL
853	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

Â©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
Â«	NULL
0022-1007/92/03/0853/10	NULL
$	NULL
2.00	NULL
Volume	NULL
175	NULL
March	NULL
1992	NULL
853-862	NULL
lated	NULL
,	NULL
either	NULL
positively	NULL
or	NULL
negatively	NULL
,	NULL
by	NULL
PKC	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
21	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
the	NULL
changes	NULL
in	NULL
phosphorylation	NULL
of	NULL
c-Jun	NULL
in	NULL
phorbol	NULL
ester-stimulated	NULL
fibroblasts	NULL
can	NULL
not	NULL
be	NULL
replicated	NULL
in	NULL
vitro	NULL
with	NULL
purified	NULL
PKC	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Experiments	NULL
with	NULL
PKC	NULL
inhibitors	NULL
have	NULL
also	NULL
been	NULL
equivocal	NULL
,	NULL
since	NULL
few	NULL
inhibitors	NULL
are	NULL
entirely	NULL
selective	NULL
for	NULL
PKC	NULL
,	NULL
and	NULL
most	NULL
are	NULL
toxic	NULL
to	NULL
untransformed	NULL
cells	NULL
at	NULL
concentrations	NULL
approaching	NULL
those	NULL
required	NULL
for	NULL
complete	NULL
inhibition	NULL
of	NULL
kinase	NULL
activity	NULL
(	NULL
22	NULL
)	NULL
.	NULL

An	NULL
alternative	NULL
method	NULL
for	NULL
assessing	NULL
the	NULL
involvement	NULL
of	NULL
PKC	NULL
has	NULL
relied	NULL
on	NULL
downmodulation	NULL
of	NULL
certain	NULL
PKC	NULL
isozymes	NULL
by	NULL
prolonged	NULL
treatment	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
phorbol	NULL
esters	NULL
(	NULL
23	NULL
)	NULL
,	NULL
a	NULL
technique	NULL
that	NULL
works	NULL
particularly	NULL
well	NULL
in	NULL
untransformed	NULL
cells	NULL
with	NULL
low	NULL
biosynthetic	NULL
rates	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
downmodulation	NULL
is	NULL
apparently	NULL
through	NULL
recruitment	NULL
of	NULL
essentially	NULL
all	NULL
the	NULL
enzyme	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
,	NULL
where	NULL
it	NULL
is	NULL
rapidly	NULL
degraded	NULL
by	NULL
a	NULL
protease	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Although	NULL
untransformed	NULL
cells	NULL
treated	NULL
in	NULL
this	NULL
manner	NULL
show	NULL
an	NULL
initial	NULL
acute	NULL
response	NULL
to	NULL
the	NULL
phorbol	NULL
ester	NULL
,	NULL
this	NULL
response	NULL
fades	NULL
rapidly	NULL
.	NULL

After	NULL
36-48	NULL
h	NULL
,	NULL
the	NULL
treated	NULL
cells	NULL
appear	NULL
similar	NULL
to	NULL
quiescent	NULL
,	NULL
untreated	NULL
T	NULL
cells	NULL
in	NULL
their	NULL
growth	NULL
rates	NULL
,	NULL
basal	NULL
levels	NULL
of	NULL
cellular	NULL
kinase	NULL
activity	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
activation-associated	NULL
genes	NULL
(	NULL
20	NULL
,	NULL
26	NULL
)	NULL
.	NULL

In	NULL
murine	NULL
thymocytes	NULL
,	NULL
Western	NULL
blotting	NULL
with	NULL
isozyme-specific	NULL
antibodies	NULL
indicates	NULL
that	NULL
the	NULL
&	NULL
and	NULL
3	NULL
PKC	NULL
isozymes	NULL
are	NULL
downmodulated	NULL
by	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
e	NULL
isozyme	NULL
is	NULL
unaffected	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Depletion	NULL
of	NULL
the	NULL
x	NULL
and	NULL
3	NULL
isozymes	NULL
by	NULL
phorbol	NULL
ester	NULL
treatment	NULL
has	NULL
been	NULL
confirmed	NULL
by	NULL
direct	NULL
measurements	NULL
of	NULL
PKC	NULL
activity	NULL
in	NULL
untransformed	NULL
murine	NULL
T	NULL
cell	NULL
clones	NULL
(	NULL
20	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
residual	NULL
e	NULL
isozyme	NULL
was	NULL
not	NULL
detected	NULL
since	NULL
it	NULL
does	NULL
not	NULL
efficiently	NULL
phos-phorylate	NULL
the	NULL
histone	NULL
substrate	NULL
used	NULL
in	NULL
the	NULL
standard	NULL
assays	NULL
for	NULL
PKC	NULL
(	NULL
28	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
chronically	NULL
treated	NULL
with	NULL
phorbol	NULL
esters	NULL
,	NULL
and	NULL
thus	NULL
depleted	NULL
for	NULL
the	NULL
ax	NULL
and	NULL
B	NULL
PKC	NULL
isozymes	NULL
,	NULL
show	NULL
no	NULL
gene	NULL
induction	NULL
or	NULL
lymphokine	NULL
secretion	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
ligands	NULL
(	NULL
20	NULL
,	NULL
26	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
downmodulated	NULL
isozymes	NULL
are	NULL
required	NULL
for	NULL
signal	NULL
transduction	NULL
through	NULL
the	NULL
TCR	NULL
.	NULL

A	NULL
less	NULL
likely	NULL
explanation	NULL
is	NULL
that	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
affects	NULL
an	NULL
unrelated	NULL
process	NULL
that	NULL
is	NULL
independently	NULL
required	NULL
for	NULL
gene	NULL
induction	NULL
and	NULL
lymphokine	NULL
secretion	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
used	NULL
the	NULL
untransformed	NULL
,	NULL
antigen-responsive	NULL
T	NULL
cell	NULL
clone	NULL
Ar-5	NULL
(	NULL
20	NULL
,	NULL
29	NULL
,	NULL
30	NULL
)	NULL
to	NULL
identify	NULL
the	NULL
PKC-sensitive	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
gene	NULL
promoter	NULL
.	NULL

Ar-5	NULL
cells	NULL
show	NULL
low	NULL
constitutive	NULL
but	NULL
strong	NULL
inducible	NULL
expression	NULL
of	NULL
nuclear	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Moreover	NULL
,	NULL
induction	NULL
of	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
activity	NULL
in	NULL
Ar-5	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
IL-2	NULL
promoter-CAT	NULL
plasmid	NULL
,	NULL
and	NULL
then	NULL
activated	NULL
through	NULL
the	NULL
TCR	NULL
,	NULL
is	NULL
completely	NULL
suppressed	NULL
by	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
,	NULL
thus	NULL
implicating	NULL
the	NULL
&	NULL
and	NULL
B	NULL
isozymes	NULL
of	NULL
PKC	NULL
in	NULL
IL-2	NULL
gene	NULL
induction	NULL
and	NULL
facilitating	NULL
the	NULL
identification	NULL
of	NULL
potentially	NULL
PKC-sensitive	NULL
mechanisms	NULL
for	NULL
IL-2	NULL
gene	NULL
induction	NULL
.	NULL

We	NULL
show	NULL
that	NULL
a	NULL
major	NULL
locus	NULL
of	NULL
PKC	NULL
responsiveness	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
the	NULL
AP-1	NULL
site	NULL
located	NULL
at	NULL
-150	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

Analysis	NULL
of	NULL
promoter	NULL
mutations	NULL
indicates	NULL
that	NULL
an	NULL
intact	NULL
NF-KB	NULL
site	NULL
is	NULL
not	NULL
required	NULL
for	NULL
II	NULL
>	NULL
2	NULL
gene	NULL
induction	NULL
in	NULL
Ar-5	NULL
T	NULL
cells	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Plasmids	NULL
.	NULL

-	NULL
The	NULL
haman	NULL
5	NULL
IL-2-CAT	NULL
plasmid	NULL
(	NULL
obtained	NULL
from	NULL
G.	NULL
Crabtree	NULL
,	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
contains	NULL
635	NULL
bp	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
and	NULL
SV40	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
tail	NULL
as	NULL
described	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
5'IL-2-CAT	NULL
plasmids	NULL
pIL-CATO	NULL
,	NULL
pIL-CAT2/1*	NULL
,	NULL
and	NULL
pILCAT2/1-M	NULL
(	NULL
obtained	NULL
from	NULL
E.	NULL
Serfling	NULL
,	NULL
Universitit	NULL
Wiirzburg	NULL
,	NULL
Wiirzburg	NULL
,	NULL
Germany	NULL
)	NULL
contain	NULL
-2000	NULL
to	NULL
-7	NULL
bp	NULL
,	NULL
-293	NULL
to	NULL
-7	NULL
bp	NULL
,	NULL
and	NULL
-293	NULL
to	NULL
-200	NULL
bp	NULL
region	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
murine	NULL
IL-2	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
Herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
(	NULL
tk	NULL
)	NULL
promoter	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
the	NULL
plasmid	NULL
pBLCAT2	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
three	NULL
human	NULL
5	NULL
'	NULL
IL-2-CAT	NULL
plasmids	NULL
bearing	NULL
mutations	NULL
in	NULL
the	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
(	NULL
obtained	NULL
from	NULL
M.	NULL
Siekevitz	NULL
,	NULL
Mount	NULL
Sinai	NULL
Medical	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
)	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
four	NULL
mutants	NULL
in	NULL
the	NULL
-150	NULL
and	NULL
-180	NULL
bp	NULL
AP-1	NULL
sites	NULL
were	NULL
constructed	NULL
in	NULL
the	NULL
human	NULL
5	NULL
'	NULL
IL-2-CAT	NULL
plasmid	NULL
(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
using	NULL
uracil-labeled	NULL
template	NULL
DNA	NULL
,	NULL
as	NULL
described	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Mutated	NULL
plasmids	NULL
were	NULL
selected	NULL
by	NULL
colony	NULL
hybridizations	NULL
using	NULL
the	NULL
mutagenic	NULL
oligonucleotide	NULL
,	NULL
and	NULL
their	NULL
identity	NULL
was	NULL
confirmed	NULL
by	NULL
restriction	NULL
mapping	NULL
and	NULL
sequencing	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
oligonucleotides	NULL
used	NULL
for	NULL
the	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
were	NULL
:	NULL
M1	NULL
:	NULL
5CAAAGACTGACTTTATGGTA	NULL
,	NULL
M2	NULL
:	NULL
5CAAAGGGTGACT	NULL
GAATGGAT	NULL
,	NULL
M3	NULL
:	NULL
5	NULL
``	NULL
TCTGATGACTCGAGGGAATT	NULL
,	NULL
and	NULL
M4	NULL
:	NULL
5	NULL
``	NULL
TCTGATGTTGCTTTGGAATT	NULL
.	NULL

The	NULL
expression	NULL
plasmids	NULL
BK28	NULL
(	NULL
human	NULL
c-Fos	NULL
,	NULL
[	NULL
34	NULL
]	NULL
)	NULL
and	NULL
pRSV-cJ	NULL
(	NULL
human	NULL
c-Jun	NULL
,	NULL
[	NULL
35	NULL
]	NULL
)	NULL
were	NULL
used	NULL
for	NULL
cotransfections	NULL
.	NULL

The	NULL
control	NULL
plasmids	NULL
that	NULL
lacked	NULL
the	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
coding	NULL
sequences	NULL
,	NULL
but	NULL
possessed	NULL
the	NULL
FBJ-MSV	NULL
proviral	NULL
LTR	NULL
and	NULL
the	NULL
RSV	NULL
LTR	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
E.	NULL
Flemington	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
.	NULL

Transfections	NULL
.	NULL

-	NULL
The	NULL
murine	NULL
T	NULL
cell	NULL
clone	NULL
Ar-5	NULL
was	NULL
cultured	NULL
in	NULL
``	NULL
T	NULL
cell	NULL
medium	NULL
,	NULL
``	NULL
consisting	NULL
of	NULL
DMEM	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
rat	NULL
T	NULL
cell	NULL
growth	NULL
factor	NULL
(	NULL
CR-fFCGF	NULL
,	NULL
Collaborative	NULL
Research	NULL
Inc.	NULL
,	NULL
Lex-ington	NULL
,	NULL
MA	NULL
)	NULL
as	NULL
a	NULL
source	NULL
of	NULL
IL-2	NULL
,	NULL
and	NULL
other	NULL
additives	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
29	NULL
,	NULL
30	NULL
,	NULL
36	NULL
)	NULL
.	NULL

For	NULL
PKC	NULL
depletion	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
200	NULL
nM	NULL
PMA	NULL
for	NULL
2	NULL
d	NULL
before	NULL
transfection	NULL
,	NULL
and	NULL
200	NULL
nM	NULL
PMA	NULL
was	NULL
included	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
until	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
.	NULL

For	NULL
transfections	NULL
,	NULL
untreated	NULL
or	NULL
PMA-treated	NULL
cells	NULL
(	NULL
2-3	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
harvested	NULL
in	NULL
log	NULL
phase	NULL
growth	NULL
(	NULL
~5	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
)	NULL
,	NULL
incubated	NULL
with	NULL
10-15	NULL
ug	NULL
of	NULL
DNA	NULL
and	NULL
100	NULL
ug/ml	NULL
DEAE-dextran	NULL
in	NULL
2	NULL
ml	NULL
DMEM	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37Â°C	NULL
,	NULL
and	NULL
split	NULL
equally	NULL
into	NULL
two	NULL
flasks	NULL
containing	NULL
10	NULL
ml	NULL
of	NULL
T	NULL
cell	NULL
medium	NULL
and	NULL
coated	NULL
with	NULL
rabbit	NULL
anti-hamster	NULL
antibodies	NULL
,	NULL
if	NULL
appropriate	NULL
.	NULL

The	NULL
transfected	NULL
cells	NULL
were	NULL
activated	NULL
the	NULL
next	NULL
day	NULL
,	NULL
harvested	NULL
24	NULL
h	NULL
later	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
,	NULL
as	NULL
described	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
conversion	NULL
of	NULL
``	NULL
C-chloramphenicol	NULL
to	NULL
its	NULL
acetylated	NULL
forms	NULL
was	NULL
quantified	NULL
using	NULL
a	NULL
Betagen	NULL
Betascope	NULL
(	NULL
Waltham	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

To	NULL
control	NULL
for	NULL
the	NULL
increase	NULL
in	NULL
protein	NULL
synthesis	NULL
in	NULL
activated	NULL
cells	NULL
,	NULL
the	NULL
protein	NULL
concentration	NULL
of	NULL
cell	NULL
extracts	NULL
was	NULL
measured	NULL
according	NULL
to	NULL
Bradford	NULL
(	NULL
38	NULL
)	NULL
and	NULL
used	NULL
to	NULL
normalize	NULL
the	NULL
measured	NULL
CAT	NULL
activity	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
plasmid	NULL
pRSVCAT	NULL
(	NULL
37	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
standard	NULL
for	NULL
transfection	NULL
efficiency	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
each	NULL
experiment	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
enhancerless	NULL
plasmid	NULL
pBL-CAT	NULL
2	NULL
(	NULL
39	NULL
)	NULL
was	NULL
not	NULL
inducible	NULL
in	NULL
transfections	NULL
and	NULL
exhibited	NULL
very	NULL
low	NULL
basal	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
stimuli	NULL
used	NULL
for	NULL
activation	NULL
were	NULL
antigen	NULL
(	NULL
arsonate-conjugated	NULL
OVA	NULL
,	NULL
100	NULL
ug/ml	NULL
)	NULL
with	NULL
2	NULL
x	NULL
10Â°	NULL
TA3	NULL
APC	NULL
(	NULL
29	NULL
,	NULL
36	NULL
)	NULL
,	NULL
anti-CD3e	NULL
(	NULL
1	NULL
%	NULL
145-2C11	NULL
hybridoma	NULL
supernatant	NULL
[	NULL
40	NULL
]	NULL
)	NULL
crosslinked	NULL
either	NULL
via	NULL
Fc	NULL
receptors	NULL
on	NULL
2	NULL
x	NULL
10Â°	NULL
TA3	NULL
cells	NULL
or	NULL
on	NULL
flasks	NULL
coated	NULL
with	NULL
300	NULL
ug/tl	NULL
rabbit	NULL
anti-hamster	NULL
antibody	NULL
(	NULL
Cappel	NULL
Laboratories	NULL
,	NULL
Cochran-ville	NULL
,	NULL
PA	NULL
)	NULL
,	NULL
or	NULL
10-nM	NULL
PMA	NULL
plus	NULL
100	NULL
nM	NULL
ionomycin	NULL
.	NULL

Activation	NULL
was	NULL
monitored	NULL
in	NULL
all	NULL
experiments	NULL
by	NULL
measuring	NULL
proliferation	NULL
or	NULL
IL-2	NULL
secretion	NULL
(	NULL
20	NULL
,	NULL
36	NULL
)	NULL
.	NULL

We	NULL
have	NULL
noticed	NULL
that	NULL
transfected	NULL
Ar-5	NULL
cells	NULL
stimulated	NULL
with	NULL
TA3	NULL
cells	NULL
and	NULL
antigen	NULL
or	NULL
anti-CD3Â¢e	NULL
show	NULL
consistently	NULL
lower	NULL
induction	NULL
of	NULL
IL-2-CAT	NULL
activity	NULL
than	NULL
cells	NULL
stimulated	NULL
with	NULL
854	NULL
AP-1	NULL
and	NULL
NFKB	NULL
Sites	NULL
in	NULL
the	NULL
Interleukin	NULL
2	NULL
Promoter	NULL
anti-CD3Â¢	NULL
that	NULL
have	NULL
been	NULL
crosslinked	NULL
using	NULL
immobilized	NULL
second	NULL
antibody	NULL
,	NULL
possibly	NULL
because	NULL
the	NULL
latter	NULL
stimulus	NULL
is	NULL
capable	NULL
of	NULL
cross-linking	NULL
a	NULL
larger	NULL
proportion	NULL
of	NULL
surface	NULL
TCR/CD3	NULL
complexes	NULL
.	NULL

Nevertheless	NULL
,	NULL
all	NULL
three	NULL
stimuli	NULL
yield	NULL
qualitatively	NULL
very	NULL
similar	NULL
results	NULL
.	NULL

For	NULL
most	NULL
experiments	NULL
,	NULL
the	NULL
use	NULL
of	NULL
anti-CD3	NULL
crosslinked	NULL
with	NULL
second	NULL
antibody	NULL
was	NULL
preferred	NULL
,	NULL
because	NULL
it	NULL
monitors	NULL
activation	NULL
solely	NULL
through	NULL
the	NULL
TCR/CD3	NULL
complex	NULL
,	NULL
uncomplicated	NULL
by	NULL
interactions	NULL
involving	NULL
other	NULL
cell-surface	NULL
receptors	NULL
such	NULL
as	NULL
CD28	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
quality	NULL
of	NULL
the	NULL
plasmid	NULL
DNAs	NULL
used	NULL
for	NULL
transfections	NULL
was	NULL
monitored	NULL
by	NULL
checking	NULL
them	NULL
all	NULL
for	NULL
equivalent	NULL
content	NULL
of	NULL
super-coiled	NULL
DNA	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
,	NULL
and	NULL
by	NULL
cotransfecting	NULL
them	NULL
with	NULL
an	NULL
RSV-hGH	NULL
(	NULL
human	NULL
growth	NULL
hormone	NULL
)	NULL
internal	NULL
control	NULL
plasmid	NULL
and	NULL
monitoring	NULL
hGH	NULL
activity	NULL
in	NULL
supernatants	NULL
and	NULL
extracts	NULL
of	NULL
unstimulated	NULL
cells	NULL
as	NULL
described	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Values	NULL
for	NULL
intracel-lular	NULL
growth	NULL
hormone	NULL
ranged	NULL
from	NULL
3	NULL
to	NULL
11	NULL
ng/2	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
values	NULL
of	NULL
secreted	NULL
hGH	NULL
ranged	NULL
from	NULL
1.85	NULL
to	NULL
5.1	NULL
ng/2	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
.	NULL

At	NULL
least	NULL
three	NULL
independent	NULL
DNA	NULL
preparations	NULL
were	NULL
tested	NULL
for	NULL
each	NULL
plasmid	NULL
.	NULL

Relative	NULL
to	NULL
the	NULL
wild-type	NULL
human	NULL
5	NULL
IL-2-CAT	NULL
plasmid	NULL
(	NULL
set	NULL
to	NULL
100	NULL
%	NULL
)	NULL
,	NULL
the	NULL
transfection	NULL
efficiency	NULL
of	NULL
the	NULL
IL-2	NULL
xB	NULL
mutants	NULL
was	NULL
as	NULL
follows	NULL
:	NULL
M1	NULL
(	NULL
80.1	NULL
%	NULL
)	NULL
,	NULL
M4	NULL
(	NULL
62.1	NULL
%	NULL
)	NULL
,	NULL
and	NULL
M5	NULL
(	NULL
60.9	NULL
%	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
relative	NULL
to	NULL
the	NULL
wild-type	NULL
human	NULL
5	NULL
'	NULL
IL2-CAT	NULL
plasmid	NULL
(	NULL
set	NULL
to	NULL
100	NULL
%	NULL
)	NULL
,	NULL
the	NULL
transfection	NULL
efficiency	NULL
of	NULL
the	NULL
AP-1	NULL
mutants	NULL
monitored	NULL
by	NULL
this	NULL
assay	NULL
was	NULL
as	NULL
follows	NULL
:	NULL
M1	NULL
(	NULL
92.6	NULL
%	NULL
)	NULL
,	NULL
M2	NULL
(	NULL
131.4	NULL
%	NULL
)	NULL
,	NULL
M3	NULL
(	NULL
265.4	NULL
%	NULL
)	NULL
,	NULL
and	NULL
M4	NULL
(	NULL
123.4	NULL
%	NULL
)	NULL
.	NULL

Cotransfection	NULL
with	NULL
internal	NULL
control	NULL
plasmids	NULL
could	NULL
not	NULL
be	NULL
performed	NULL
in	NULL
our	NULL
experiments	NULL
,	NULL
since	NULL
all	NULL
the	NULL
internal	NULL
control	NULL
plasmids	NULL
that	NULL
we	NULL
have	NULL
tested	NULL
were	NULL
induced	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
since	NULL
induction	NULL
of	NULL
the	NULL
CAT	NULL
plasmids	NULL
was	NULL
decreased	NULL
when	NULL
internal	NULL
control	NULL
plasmids	NULL
were	NULL
cotrans-fected	NULL
,	NULL
apparently	NULL
because	NULL
of	NULL
competition	NULL
between	NULL
the	NULL
CAT	NULL
plasmids	NULL
and	NULL
the	NULL
internal	NULL
control	NULL
plasmids	NULL
for	NULL
relevant	NULL
transcription	NULL
factors	NULL
.	NULL

These	NULL
problems	NULL
are	NULL
likely	NULL
to	NULL
reflect	NULL
lower	NULL
resting	NULL
,	NULL
as	NULL
well	NULL
as	NULL
lower	NULL
inducible	NULL
levels	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
untransformed	NULL
T	NULL
cell	NULL
clones	NULL
,	NULL
compared	NULL
with	NULL
the	NULL
transformed	NULL
T	NULL
cells	NULL
previously	NULL
used	NULL
for	NULL
studies	NULL
of	NULL
II-2	NULL
promoter	NULL
activation	NULL
(	NULL
JURKAT	NULL
,	NULL
EL-4	NULL
,	NULL
and	NULL
LBRM-33	NULL
[	NULL
11	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
16	NULL
]	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assays	NULL
.	NULL

-	NULL
The	NULL
following	NULL
oligonucleotides	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
in	NULL
gel-shift	NULL
assays	NULL
:	NULL
Murine	NULL
Ig	NULL
Â«	NULL
k	NULL
enhancer	NULL
KB	NULL
site	NULL
(	NULL
42	NULL
)	NULL
:	NULL
5'gatcCAGAGGGGACTTTCCGAGA	NULL
;	NULL
3'Ig	NULL
Â«	NULL
B	NULL
mu	NULL
a	NULL
NFAT	NULL
NF-kB	NULL
_	NULL
APA	NULL
_	NULL
CD28RC	NULL
-	NULL
APA	NULL
-H	NULL
--	NULL
-	NULL
___	NULL
1-2	NULL
|	NULL
|	NULL
|	NULL
293	NULL
250	NULL
204	NULL
185	NULL
164	NULL
156	NULL
1.4	NULL
3	NULL
1	NULL
.	NULL

_	NULL
12	NULL
25	NULL
o	NULL
8	NULL
;	NULL
3	NULL
.	NULL

2	NULL
8	NULL
-	NULL
os	NULL
g	NULL
1.5	NULL
a	NULL
06	NULL
x	NULL
1	NULL
*	NULL
``	NULL
ao4	NULL
0.2	NULL
0.5	NULL
0	NULL
o	NULL
L	NULL
Untreated	NULL
-	NULL
PKC	NULL
depleted	NULL
Murine	NULL
S'IL2-CAT	NULL
Untreated	NULL
-	NULL
PKC	NULL
depleted	NULL
Human	NULL
S'IL2-CAT	NULL
[	NULL
2	NULL
]	NULL
Uninduced	NULL
_	NULL
fill	NULL
Induced	NULL
855	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

tant	NULL
:	NULL
S'gatcCAGAGGGGACTTGAAGAGA	NULL
;	NULL
5'lg	NULL
Â«	NULL
kB	NULL
mutant	NULL
:	NULL
5'gatcCAGAATTCACTTTCCGAGA	NULL
;	NULL
Wild-type	NULL
murine	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
(	NULL
TCE	NULL
,	NULL
,	NULL
[	NULL
14	NULL
]	NULL
)	NULL
:	NULL
5'gatcACCAAGAGGGATTTCACCTAAATCC	NULL
;	NULL
-150	NULL
bp	NULL
murine	NULL
AP-1	NULL
site	NULL
(	NULL
TRE	NULL
,	NULL
[	NULL
14	NULL
]	NULL
)	NULL
:	NULL
5'gatcAATTCCAGAG-AGTCATCAGA	NULL
;	NULL
-180	NULL
bp	NULL
murine	NULL
APA	NULL
site	NULL
[	NULL
14	NULL
]	NULL
)	NULL
:	NULL
5'-gatcclAAATCCATTCAGTCAGTGTATG	NULL
;	NULL
Murine	NULL
NFAT	NULL
site	NULL
(	NULL
Pu-boxg	NULL
,	NULL
[	NULL
14	NULL
,	NULL
15	NULL
]	NULL
)	NULL
:	NULL
5gatcGCCCAAAGAGGAAAATTTGTTTC-ATACAG	NULL
;	NULL
Human	NULL
metallothionein	NULL
AP-1	NULL
site	NULL
(	NULL
43	NULL
)	NULL
:	NULL
5'tegaCGTGAC-TCAGCGCGC	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
endlabeled	NULL
with	NULL
y	NULL
[	NULL
``	NULL
Â°P	NULL
]	NULL
-ATP	NULL
and	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
33	NULL
)	NULL
and	NULL
purified	NULL
on	NULL
12	NULL
%	NULL
acrylamide	NULL
gels	NULL
.	NULL

Small-scale	NULL
nuclear	NULL
extracts	NULL
were	NULL
made	NULL
from	NULL
2	NULL
x	NULL
10	NULL
``	NULL
unactivated	NULL
or	NULL
activated	NULL
Ar-5	NULL
cells	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Unless	NULL
otherwise	NULL
stated	NULL
,	NULL
cells	NULL
were	NULL
activated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
anti-CD3e	NULL
antibody	NULL
which	NULL
was	NULL
crosslinked	NULL
using	NULL
immobilized	NULL
second	NULL
antibody	NULL
.	NULL

For	NULL
each	NULL
binding	NULL
reaction	NULL
,	NULL
10,000	NULL
cpm	NULL
(	NULL
~0.2-0.5	NULL
ng	NULL
)	NULL
of	NULL
endlabeled	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
5-8-ug	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
3	NULL
ug	NULL
sheared	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
reaction	NULL
was	NULL
performed	NULL
for	NULL
5-10	NULL
min	NULL
(	NULL
AP-1	NULL
)	NULL
,	NULL
or	NULL
15-20	NULL
min	NULL
(	NULL
NFAT-1	NULL
and	NULL
IL-2	NULL
Â«	NULL
B	NULL
)	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
resulting	NULL
complexes	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
at	NULL
room	NULL
temperature	NULL
on	NULL
4	NULL
%	NULL
acrylamide	NULL
gels	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
Induction	NULL
of	NULL
the	NULL
IL-2	NULL
Promoter	NULL
Is	NULL
Sensitive	NULL
to	NULL
Chronic	NULL
Phorbol	NULL
Ester	NULL
Treatment	NULL
.	NULL

-	NULL
The	NULL
antigen-responsive	NULL
murine	NULL
T	NULL
cell	NULL
clone	NULL
Ar-5	NULL
(	NULL
29	NULL
)	NULL
was	NULL
left	NULL
untreated	NULL
or	NULL
depleted	NULL
of	NULL
PKC	NULL
by	NULL
prolonged	NULL
treatment	NULL
with	NULL
a	NULL
high	NULL
concentration	NULL
of	NULL
PMA	NULL
(	NULL
200	NULL
nM	NULL
for	NULL
48	NULL
h	NULL
)	NULL
.	NULL

As	NULL
mentioned	NULL
previously	NULL
,	NULL
this	NULL
treatment	NULL
results	NULL
in	NULL
selective	NULL
degradation	NULL
of	NULL
the	NULL
&	NULL
and	NULL
3	NULL
isozymes	NULL
of	NULL
PKC	NULL
,	NULL
but	NULL
not	NULL
the	NULL
e	NULL
isozyme	NULL
in	NULL
murine	NULL
thymocytes	NULL
(	NULL
27	NULL
)	NULL
,	NULL
and	NULL
abrogates	NULL
induction	NULL
of	NULL
IL-2	NULL
mRNA	NULL
in	NULL
Ar-5	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Untreated	NULL
and	NULL
PMA-treated	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
plasmids	NULL
containing	NULL
the	NULL
5	NULL
'	NULL
sequences	NULL
of	NULL
either	NULL
the	NULL
human	NULL
or	NULL
murine	NULL
IL-2	NULL
promoters	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
(	NULL
14	NULL
,	NULL
31	NULL
}	NULL
.	NULL

The	NULL
transfected	NULL
NFAT	NULL
OCT	NULL
-pe	NULL
-f	NULL
142	NULL
90	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
Sensitivity	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
to	NULL
PKC	NULL
depletion	NULL
by	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
.	NULL

(	NULL
a	NULL
)	NULL
A	NULL
schematic	NULL
diagram	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
showing	NULL
the	NULL
locations	NULL
of	NULL
sites	NULL
thought	NULL
to	NULL
be	NULL
important	NULL
for	NULL
promoter	NULL
induction	NULL
.	NULL

(	NULL
*	NULL
}	NULL
Weaker	NULL
binding	NULL
sites	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Induction	NULL
of	NULL
CAT	NULL
activity	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
indicated	NULL
plasmids	NULL
into	NULL
Ar-5	NULL
cells	NULL
.	NULL

Untreated	NULL
cells	NULL
or	NULL
cells	NULL
treated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
were	NULL
transfected	NULL
with	NULL
human	NULL
(	NULL
eft	NULL
)	NULL
or	NULL
murine	NULL
(	NULL
center	NULL
)	NULL
5'IL	NULL
2-CAT	NULL
plasmids	NULL
or	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
a	NULL
trimer	NULL
of	NULL
the	NULL
NFAT	NULL
and	NULL
OCT	NULL
sites	NULL
II	NULL
PKC	NULL
depleted	NULL
Murine	NULL
NFAT/Oct-3xCAT	NULL
{	NULL
right	NULL
)	NULL
,	NULL
and	NULL
stimulated	NULL
with	NULL
TA3	NULL
cells	NULL
and	NULL
antigen	NULL
or	NULL
anti-CD3e	NULL
.	NULL

A	NULL
representative	NULL
experiment	NULL
using	NULL
TA3	NULL
cells	NULL
and	NULL
anti-CD3e	NULL
is	NULL
shown	NULL
.	NULL

At	NULL
least	NULL
three	NULL
similar	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
independent	NULL
preparations	NULL
of	NULL
each	NULL
plasmid	NULL
.	NULL

Untreated	NULL
x	NULL
xo	NULL
%	NULL
*	NULL
%	NULL
gks	NULL
WT	NULL
AGGGATTTCAC	NULL
124	NULL
|	NULL
M1	NULL
CTC	NULL
IL2	NULL
KB	NULL
|	NULL
py	NULL
cea	NULL
6	NULL
CMS	NULL
CTCCGAA	NULL
-	NULL
@	NULL
2	NULL
0	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
1	NULL
*	NULL
@	NULL
=	NULL
Â»	NULL
&	NULL
pRSVCAT|	NULL
Human	NULL
S'IL2-CAT	NULL
|	NULL
Mutant	NULL
M1	NULL
PMA	NULL
pretreated	NULL
|	NULL
-	NULL
+	NULL
-	NULL
-	NULL
+	NULL
+	NULL
|	NULL
-	NULL
-	NULL
+	NULL
+	NULL
X-linked	NULL
aCD3	NULL
|	NULL
-	NULL
-	NULL
2+	NULL
-	NULL
+0	NULL
]	NULL
-	NULL
+	NULL
+0	NULL
|	NULL
%	NULL
conversion	NULL
|g3.5	NULL
1s	NULL
|0.3	NULL
1.7	NULL
0.2	NULL
0.2	NULL
)	NULL
0.25	NULL
1.3	NULL
04	NULL
0.2	NULL
Fold	NULL
induction	NULL
6.0	NULL
-	NULL
|	NULL
5.4	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
l	NULL
,	NULL
|	NULL
â	NULL
0900000	NULL
Mutant	NULL
M4	NULL
Mutant	NULL
MS	NULL
PMA	NULL
pretreated	NULL
|	NULL
.	NULL

R	NULL
+	NULL
+	NULL
-	NULL
R	NULL
+	NULL
+	NULL
X-linked	NULL
aCD3	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
4	NULL
+	NULL
%	NULL
conversion	NULL
_	NULL
|pa	NULL
53	NULL
0.2	NULL
0.3	NULL
|	NULL
0.2	NULL
5.1	NULL
0.25	NULL
0.5	NULL
Fold	NULL
induction	NULL
16	NULL
cells	NULL
were	NULL
stimulated	NULL
24-h	NULL
later	NULL
with	NULL
either	NULL
antigen	NULL
(	NULL
arsonate-conjugated	NULL
OVA	NULL
;	NULL
Ars-OVA	NULL
)	NULL
(	NULL
29	NULL
)	NULL
presented	NULL
on	NULL
TA3	NULL
cells	NULL
,	NULL
or	NULL
with	NULL
a	NULL
mAb	NULL
to	NULL
the	NULL
TCR/CD3	NULL
complex	NULL
(	NULL
145-2C11	NULL
,	NULL
anti-CD3Â¢	NULL
)	NULL
that	NULL
was	NULL
crosslinked	NULL
using	NULL
either	NULL
TA3	NULL
cells	NULL
or	NULL
an	NULL
immobilized	NULL
second	NULL
antibody	NULL
.	NULL

The	NULL
cell	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
18-24	NULL
h	NULL
later	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Both	NULL
human	NULL
and	NULL
murine	NULL
5	NULL
``	NULL
IL-2-CAT	NULL
constructs	NULL
were	NULL
induced	NULL
three-fivefold	NULL
after	NULL
activation	NULL
of	NULL
Ar-5	NULL
cells	NULL
by	NULL
TA3	NULL
cells	NULL
and	NULL
antigen	NULL
or	NULL
anti-CD3	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
b	NULL
,	NULL
left	NULL
and	NULL
center	NULL
)	NULL
.	NULL

No	NULL
induction	NULL
was	NULL
seen	NULL
if	NULL
the	NULL
cells	NULL
were	NULL
depleted	NULL
of	NULL
PKC	NULL
by	NULL
phorbol	NULL
ester	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
b	NULL
,	NULL
left	NULL
and	NULL
center	NULL
)	NULL
.	NULL

This	NULL
was	NULL
expected	NULL
since	NULL
IL-2	NULL
mRNA	NULL
and	NULL
protein	NULL
are	NULL
not	NULL
induced	NULL
after	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
pRSVCAT	NULL
,	NULL
which	NULL
is	NULL
constitutively	NULL
expressed	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
and	NULL
was	NULL
equivalently	NULL
expressed	NULL
in	NULL
untreated	NULL
and	NULL
PMA-pretreated	NULL
cells	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
PMA-pretreated	NULL
cells	NULL
did	NULL
not	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
and	NULL
ionomycin	NULL
nor	NULL
to	NULL
anti-CD3Â¢	NULL
antibody	NULL
,	NULL
confirming	NULL
that	NULL
they	NULL
were	NULL
depleted	NULL
of	NULL
the	NULL
relevant	NULL
(	NULL
a	NULL
and	NULL
3	NULL
)	NULL
PKC	NULL
isozymes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

24	NULL
Induction	NULL
of	NULL
an	NULL
NFAT/Oct	NULL
Trimer	NULL
Is	NULL
Insensitive	NULL
to	NULL
Chronic	NULL
Phorbol	NULL
Ester	NULL
Treatment	NULL
.	NULL

-	NULL
The	NULL
human	NULL
and	NULL
mouse	NULL
IL	NULL
>	NULL
2	NULL
promoters	NULL
share	NULL
binding	NULL
sites	NULL
for	NULL
several	NULL
known	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
region	NULL
extending	NULL
~300	NULL
bases	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
a	NULL
)	NULL
.	NULL

This	NULL
region	NULL
contains	NULL
sites	NULL
for	NULL
the	NULL
nuclear	NULL
factors	NULL
NFAT-1	NULL
,	NULL
Oct-1/Oct-2	NULL
,	NULL
NF-KB	NULL
,	NULL
CD28RC	NULL
,	NULL
and	NULL
AP-1	NULL
(	NULL
11-19	NULL
)	NULL
.	NULL

NFAT	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
activities	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
phorbol	NULL
esters	NULL
and/or	NULL
calcium	NULL
ionophores	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
JURKAT	NULL
[	NULL
12	NULL
,	NULL
13	NULL
]	NULL
and	NULL
EL4	NULL
cells	NULL
[	NULL
14	NULL
]	NULL
)	NULL
,	NULL
and	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
(	NULL
7	NULL
,	NULL
45	NULL
,	NULL
46	NULL
)	NULL
,	NULL
implicating	NULL
PKC	NULL
and/or	NULL
calcium	NULL
dependent	NULL
kinases	NULL
in	NULL
their	NULL
activation	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
NFAT-1	NULL
and	NULL
Oct	NULL
sites	NULL
contributed	NULL
to	NULL
the	NULL
PKC	NULL
responsiveness	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
we	NULL
transfected	NULL
a	NULL
CAT	NULL
plasmid	NULL
(	NULL
pIL-CAT2/1-M	NULL
;	NULL
[	NULL
14	NULL
]	NULL
)	NULL
containing	NULL
a	NULL
trimer	NULL
of	NULL
the	NULL
murine	NULL
NFAT-1/Oct	NULL
site	NULL
(	NULL
-293	NULL
to	NULL
-200	NULL
bp	NULL
relative	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
)	NULL
into	NULL
untreated	NULL
and	NULL
phorbol	NULL
ester-treated	NULL
Ar-5	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
b	NULL
,	NULL
right	NULL
)	NULL
.	NULL

The	NULL
NFAT	NULL
1/Oct	NULL
construct	NULL
was	NULL
induced	NULL
strongly	NULL
under	NULL
both	NULL
conditions	NULL
856	NULL
AP-1	NULL
and	NULL
NFKB	NULL
Sites	NULL
in	NULL
the	NULL
Interleukin	NULL
2	NULL
Promoter	NULL
AGGGATTTCAC	NULL
GG	NULL
@	NULL
G	NULL
@	NULL
aGaCcTTTCC	NULL
Labelled	NULL
probe	NULL
:	NULL
IL2	NULL
kB	NULL
Competitors	NULL
:	NULL
lg	NULL
kB	NULL
5	NULL
'	NULL
Mut	NULL
ATTC	NULL
3	NULL
'	NULL
Mut	NULL
GAA	NULL
Induced	NULL
ae	NULL
o	NULL
won	NULL
suse	NULL
.	NULL

Â»	NULL
:	NULL
None	NULL
Self	NULL
Ig	NULL
kB	NULL
_	NULL
5'Â¢	NULL
Mut	NULL
_	NULL
3	NULL
'	NULL
Mut	NULL
20	NULL
40	NULL
20	NULL
40	NULL
20	NULL
40	NULL
20	NULL
40	NULL
*	NULL
,	NULL
1	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
b	NULL
,	NULL
right	NULL
)	NULL
.	NULL

Although	NULL
this	NULL
experiment	NULL
does	NULL
not	NULL
distinguish	NULL
between	NULL
the	NULL
individual	NULL
contributions	NULL
of	NULL
NFAT-1	NULL
and	NULL
Oct	NULL
sites	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
downmodulation	NULL
of	NULL
PKC	NULL
activity	NULL
(	NULL
or	NULL
any	NULL
other	NULL
effect	NULL
of	NULL
chronic	NULL
PMA	NULL
pretreatment	NULL
)	NULL
does	NULL
not	NULL
compromise	NULL
their	NULL
enhancer	NULL
function	NULL
in	NULL
Ar-5	NULL
cells	NULL
.	NULL

Likewise	NULL
,	NULL
phorbol	NULL
ester	NULL
treatment	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
protein	NULL
complex	NULL
that	NULL
bound	NULL
specifically	NULL
to	NULL
the	NULL
NFAT-1	NULL
site	NULL
in	NULL
gel-shift	NULL
assays	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
b	NULL
,	NULL
lanes	NULL
9-12	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
effect	NULL
of	NULL
PKC	NULL
depletion	NULL
on	NULL
induction	NULL
of	NULL
the	NULL
NFAT-1	NULL
site	NULL
trimer	NULL
,	NULL
and	NULL
on	NULL
appearance	NULL
of	NULL
NFAT-1	NULL
binding	NULL
activity	NULL
in	NULL
a	NULL
gel-shift	NULL
assay	NULL
,	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
suggestion	NULL
that	NULL
calcium-dependent	NULL
processes	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NFAT-1	NULL
(	NULL
18	NULL
)	NULL
.	NULL

However	NULL
PKC	NULL
isozymes	NULL
(	NULL
such	NULL
as	NULL
the	NULL
e	NULL
isozyme	NULL
)	NULL
that	NULL
are	NULL
not	NULL
downmodulated	NULL
by	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
might	NULL
also	NULL
be	NULL
involved	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
NF-KB	NULL
Site	NULL
Do	NULL
Not	NULL
Decrease	NULL
IL-2	NULL
Promoter	NULL
Induction	NULL
.	NULL

-	NULL
These	NULL
experiments	NULL
suggested	NULL
that	NULL
the	NULL
NFAT	NULL
and	NULL
Oct	NULL
sites	NULL
were	NULL
not	NULL
PKC	NULL
responsive	NULL
(	NULL
as	NULL
defined	NULL
by	NULL
their	NULL
insensitivity	NULL
to	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
)	NULL
,	NULL
and	NULL
hence	NULL
that	NULL
857	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

|	NULL
-l	NULL
Free	NULL
probe	NULL
Competitor	NULL
(	NULL
ng	NULL
)	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
unaffected	NULL
by	NULL
mutations	NULL
of	NULL
the	NULL
Â«	NULL
B	NULL
site	NULL
that	NULL
abolish	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Induction	NULL
of	NULL
CAT	NULL
activity	NULL
from	NULL
wild-type	NULL
(	NULL
lanes	NULL
3-6	NULL
)	NULL
and	NULL
Â«	NULL
B	NULL
site	NULL
mutant	NULL
promoters	NULL
(	NULL
lanes	NULL
7-18	NULL
)	NULL
after	NULL
transfection	NULL
into	NULL
untreated	NULL
Ar-5	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
11	NULL
,	NULL
12	NULL
,	NULL
15	NULL
,	NULL
and	NULL
16	NULL
)	NULL
or	NULL
cells	NULL
depleted	NULL
of	NULL
PKC	NULL
by	NULL
pretreatment	NULL
with	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
10	NULL
,	NULL
13	NULL
,	NULL
14	NULL
,	NULL
17	NULL
,	NULL
and	NULL
18	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
unstimulated	NULL
(	NULL
lanes	NULL
1-3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
11	NULL
,	NULL
13	NULL
,	NULL
15	NULL
,	NULL
and	NULL
17	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
anti-CD3Â¢	NULL
crosslinked	NULL
with	NULL
immobilized	NULL
second	NULL
antibody	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
16	NULL
,	NULL
and	NULL
18	NULL
)	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
of	NULL
four	NULL
performed	NULL
with	NULL
each	NULL
plasmid	NULL
,	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
plasmid	NULL
pRSVCAT	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
for	NULL
transfecta-bility	NULL
of	NULL
the	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
PMA	NULL
downregulated	NULL
Ar-5	NULL
cells	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

(	NULL
'Top	NULL
)	NULL
Sequences	NULL
of	NULL
the	NULL
Â«	NULL
B	NULL
site	NULL
mutants	NULL
M1	NULL
,	NULL
M4	NULL
,	NULL
and	NULL
MS	NULL
are	NULL
compared	NULL
with	NULL
the	NULL
sequences	NULL
of	NULL
the	NULL
wild-type	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
and	NULL
the	NULL
Ig	NULL
x	NULL
gene	NULL
enhancer	NULL
KB	NULL
site	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Binding	NULL
of	NULL
an	NULL
inducible	NULL
NF-	NULL
Â«	NULL
B-like	NULL
nuclear	NULL
factor	NULL
from	NULL
Ar-5	NULL
cells	NULL
to	NULL
the	NULL
IL-2KB	NULL
site	NULL
.	NULL

Cells	NULL
were	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
activated	NULL
with	NULL
crosslinked	NULL
anti-CD3Â¢	NULL
(	NULL
lanes	NULL
2-10	NULL
)	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
incubated	NULL
with	NULL
a	NULL
labeled	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
unlabeled	NULL
competitors	NULL
as	NULL
indicated	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

(	NULL
Â«	NULL
@	NULL
)	NULL
Positions	NULL
of	NULL
the	NULL
free	NULL
probe	NULL
and	NULL
the	NULL
inducible	NULL
retarded	NULL
complex	NULL
.	NULL

(	NULL
Top	NULL
)	NULL
Sequences	NULL
of	NULL
the	NULL
relevant	NULL
regions	NULL
of	NULL
the	NULL
IL-2	NULL
Â«	NULL
B	NULL
probe	NULL
and	NULL
of	NULL
the	NULL
unlabeled	NULL
competitors	NULL
.	NULL

the	NULL
PKC-responsive	NULL
site	NULL
(	NULL
s	NULL
)	NULL
were	NULL
located	NULL
downstream	NULL
of	NULL
-200	NULL
bp	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Two	NULL
likely	NULL
candidates	NULL
were	NULL
the	NULL
NFKB	NULL
and	NULL
AP-1	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
a	NULL
)	NULL
,	NULL
which	NULL
can	NULL
bind	NULL
purified	NULL
NF-kB	NULL
and	NULL
AP-1	NULL
proteins	NULL
as	NULL
well	NULL
as	NULL
PMA-inducible	NULL
nuclear	NULL
factors	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
(	NULL
13	NULL
,	NULL
14	NULL
,	NULL
42	NULL
,	NULL
47	NULL
)	NULL
.	NULL

We	NULL
used	NULL
site-specific	NULL
mutants	NULL
to	NULL
determine	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
NF-KB	NULL
site	NULL
in	NULL
IL-2	NULL
promoter	NULL
induction	NULL
.	NULL

Three	NULL
5	NULL
'	NULL
IL-2-CAT	NULL
plasmids	NULL
derived	NULL
from	NULL
mutations	NULL
in	NULL
the	NULL
NF-KB	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
gene	NULL
(	NULL
13	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
a	NULL
,	NULL
top	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
Ar-5	NULL
cells	NULL
.	NULL

All	NULL
three	NULL
mutant	NULL
promoters	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
a	NULL
,	NULL
lanes	NULL
7	NULL
,	NULL
8	NULL
;	NULL
11	NULL
,	NULL
12	NULL
;	NULL
and	NULL
15	NULL
and	NULL
16	NULL
)	NULL
could	NULL
be	NULL
activated	NULL
at	NULL
least	NULL
as	NULL
well	NULL
as	NULL
the	NULL
wild-type	NULL
promoter	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
effect	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
site	NULL
was	NULL
not	NULL
due	NULL
to	NULL
any	NULL
differences	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
plasmids	NULL
to	NULL
be	NULL
transfected	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
internal	NULL
controls	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
mutants	NULL
M4	NULL
and	NULL
MS	NULL
(	NULL
lanes	NULL
11	NULL
,	NULL
12	NULL
;	NULL
and	NULL
15	NULL
,	NULL
16	NULL
)	NULL
consistently	NULL
showed	NULL
two	NULL
to	NULL
fourfold	NULL
higher	NULL
induction	NULL
than	NULL
the	NULL
wild-type	NULL
promoter	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
despite	NULL
being	NULL
lower	NULL
in	NULL
transfection	NULL
efficiency	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
perhaps	NULL
the	NULL
IL-2	NULL
NF-KB	NULL
site	NULL
is	NULL
a	NULL
target	NULL
8	NULL
__	NULL
__	NULL
â¬	NULL
8	NULL
1soap4	NULL
__	NULL
&	NULL
ATCCAEQAGTCAECTTTGGGGGTWAMGAMTTCCï¬AGï¬	NULL
'	NULL
CATCAGA	NULL
AA	NULL
CC	NULL
CTC	NULL
CAA	NULL
M1	NULL
M2	NULL
M3	NULL
-	NULL
M4	NULL
pRSVCAT	NULL
_	NULL
Human	NULL
S'IL2-CAT	NULL
M1	NULL
M2	NULL
M3	NULL
M4	NULL
___	NULL
_	NULL
X-linked	NULL
acos	NULL
____________j	NULL
Fold	NULL
induction	NULL
84.7	NULL
63.2	NULL
57.7	NULL
2.3	NULL
4.2	NULL
*	NULL
*e	NULL
*	NULL
-150	NULL
AP-1	NULL
MT	NULL
AP-1	NULL
NFAT-1	NULL
-o-	NULL
ot	NULL
oB	NULL
c-	NULL
o-	NULL
o	NULL
$	NULL
o	NULL
$	NULL
o-	NULL
-	NULL
+	NULL
+	NULL
PMA	NULL
pretreatment	NULL
Woo	NULL
,	NULL
auath	NULL
#	NULL
-	NULL
.	NULL

-	NULL
<	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Lanes	NULL
858	NULL
AP-1	NULL
and	NULL
NFKB	NULL
Sites	NULL
in	NULL
the	NULL
Interleukin	NULL
2	NULL
Promoter	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Site-specific	NULL
mutations	NULL
in	NULL
the	NULL
downstream	NULL
AP-1	NULL
site	NULL
markedly	NULL
decrease	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
vivo	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Induction	NULL
of	NULL
CAT	NULL
activity	NULL
from	NULL
wild-type	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
and	NULL
mutant	NULL
(	NULL
lanes	NULL
4-7	NULL
)	NULL
IL-2	NULL
promoters	NULL
after	NULL
transfection	NULL
into	NULL
Ar-5	NULL
cells	NULL
.	NULL

Lane	NULL
1	NULL
shows	NULL
the	NULL
activity	NULL
obtained	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
control	NULL
pRSVCAT	NULL
plasmid	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
unstimulated	NULL
cells	NULL
;	NULL
lanes	NULL
3-7	NULL
,	NULL
cells	NULL
stimulated	NULL
with	NULL
crosslinked	NULL
anti-CD3e	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
,	NULL
of	NULL
six	NULL
to	NULL
eight	NULL
using	NULL
different	NULL
methods	NULL
of	NULL
activation	NULL
,	NULL
is	NULL
shown	NULL
.	NULL

There	NULL
was	NULL
no	NULL
difference	NULL
in	NULL
the	NULL
background	NULL
activity	NULL
of	NULL
the	NULL
wild-type	NULL
and	NULL
mutant	NULL
promoters	NULL
in	NULL
unstimulated	NULL
cells	NULL
.	NULL

(	NULL
Top	NULL
)	NULL
Sequences	NULL
of	NULL
the	NULL
mutations	NULL
in	NULL
the	NULL
two	NULL
AP-1	NULL
sites	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

(	NULL
b	NULL
)	NULL
PKC-sensitive	NULL
binding	NULL
of	NULL
a	NULL
nuclear	NULL
factor	NULL
from	NULL
activated	NULL
Ar-5	NULL
cells	NULL
to	NULL
the	NULL
downstream	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Cells	NULL
were	NULL
untreated	NULL
(	NULL
``	NULL
-	NULL
``	NULL
;	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
)	NULL
or	NULL
depleted	NULL
of	NULL
kinase	NULL
C	NULL
by	NULL
prolonged	NULL
exposure	NULL
to	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
(	NULL
``	NULL
+	NULL
``	NULL
;	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
11	NULL
,	NULL
and	NULL
12	NULL
)	NULL
,	NULL
and	NULL
left	NULL
unstimulated	NULL
(	NULL
``	NULL
U	NULL
``	NULL
;	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
11	NULL
)	NULL
,	NULL
or	NULL
induced	NULL
with	NULL
crosslinked	NULL
anti-CD3	NULL
(	NULL
``	NULL
F	NULL
``	NULL
;	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
made	NULL
,	NULL
incubated	NULL
with	NULL
labeled	NULL
oligonucleotides	NULL
corresponding	NULL
-	NULL
<	NULL
ll-	NULL
Free	NULL
probe	NULL
to	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
,	NULL
the	NULL
metallothionein	NULL
AP-1	NULL
site	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
,	NULL
or	NULL
the	NULL
NFAT-1	NULL
site	NULL
(	NULL
lanes	NULL
9-12	NULL
)	NULL
,	NULL
Â«	NULL
<	NULL
-	NULL
Free	NULL
probe	NULL
and	NULL
analyzed	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
free	NULL
probes	NULL
and	NULL
of	NULL
the	NULL
inducible	NULL
retarded	NULL
complexes	NULL
are	NULL
indicated	NULL
.	NULL

for	NULL
negative	NULL
regulation	NULL
in	NULL
Ar-5	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
same	NULL
NF-	NULL
Â«	NULL
B	NULL
mutations	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
decrease	NULL
induction	NULL
in	NULL
PHA/PMA-stimulated	NULL
JURKAT	NULL
cells	NULL
by	NULL
as	NULL
much	NULL
as	NULL
80	NULL
%	NULL
(	NULL
13	NULL
)	NULL
.	NULL

This	NULL
discrepancy	NULL
may	NULL
reflect	NULL
a	NULL
difference	NULL
between	NULL
primary	NULL
and	NULL
transformed	NULL
T	NULL
cells	NULL
.	NULL

Alternatively	NULL
,	NULL
stimulation	NULL
via	NULL
PMA	NULL
and	NULL
PHA	NULL
may	NULL
not	NULL
physiologically	NULL
mimic	NULL
activation	NULL
by	NULL
antigen	NULL
or	NULL
antibodies	NULL
to	NULL
the	NULL
TCR/CD3	NULL
complex	NULL
.	NULL

Nevertheless	NULL
,	NULL
Ar-5	NULL
cells	NULL
and	NULL
JURKAT	NULL
cells	NULL
are	NULL
unlikely	NULL
to	NULL
have	NULL
completely	NULL
different	NULL
requirements	NULL
for	NULL
IL-2	NULL
promoter	NULL
activation	NULL
,	NULL
since	NULL
a	NULL
mutant	NULL
promoter	NULL
with	NULL
an	NULL
internal	NULL
deletion	NULL
encompassing	NULL
the	NULL
NF-KB	NULL
site	NULL
was	NULL
induced	NULL
as	NULL
well	NULL
as	NULL
the	NULL
wild-type	NULL
IL2	NULL
promoter	NULL
in	NULL
PHA/PMA-stimulated	NULL
JURKAT	NULL
cells	NULL
12	NULL
,	NULL
48	NULL
)	NULL
.	NULL

(	NULL
Like	NULL
)	NULL
induction	NULL
of	NULL
the	NULL
wild-type	NULL
promoter	NULL
,	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
mutants	NULL
was	NULL
also	NULL
abrogated	NULL
by	NULL
PMA	NULL
pretreatment	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
a	NULL
,	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
;	NULL
9	NULL
,	NULL
10	NULL
;	NULL
13	NULL
,	NULL
14	NULL
;	NULL
and	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

This	NULL
result	NULL
confirms	NULL
that	NULL
the	NULL
NF-KB	NULL
site	NULL
does	NULL
not	NULL
represent	NULL
the	NULL
PKC-responsive	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
binds	NULL
purified	NULL
NF-KB	NULL
in	NULL
vitro	NULL
with	NULL
~10-fold	NULL
lower	NULL
affinity	NULL
than	NULL
the	NULL
Ig	NULL
Â«	NULL
B	NULL
site	NULL
(	NULL
49	NULL
)	NULL
,	NULL
and	NULL
its	NULL
activity	NULL
in	NULL
vivo	NULL
may	NULL
be	NULL
further	NULL
reduced	NULL
or	NULL
modified	NULL
by	NULL
interactions	NULL
with	NULL
other	NULL
nuclear	NULL
factors	NULL
(	NULL
47	NULL
,	NULL
50	NULL
)	NULL
;	NULL
thus	NULL
,	NULL
it	NULL
is	NULL
not	NULL
surprising	NULL
that	NULL
it	NULL
appears	NULL
non-functional	NULL
in	NULL
our	NULL
assays	NULL
.	NULL

Although	NULL
mutations	NULL
in	NULL
the	NULL
NF-KB	NULL
site	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
induction	NULL
of	NULL
IL-2-CAT	NULL
activity	NULL
,	NULL
we	NULL
detected	NULL
binding	NULL
of	NULL
an	NULL
inducible	NULL
nuclear	NULL
factor	NULL
to	NULL
the	NULL
NF-KB	NULL
site	NULL
in	NULL
gel-shift	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
b	NULL
)	NULL
.	NULL

A	NULL
double-stranded	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
murine	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
(	NULL
-210	NULL
to	NULL
-186	NULL
bp	NULL
)	NULL
was	NULL
labeled	NULL
and	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
Ar-5	NULL
cells	NULL
that	NULL
were	NULL
either	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
crosslinked	NULL
anti-CD3e	NULL
.	NULL

Two	NULL
specific	NULL
retarded	NULL
bands	NULL
were	NULL
observed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
stimulated	NULL
,	NULL
but	NULL
not	NULL
unstimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
b	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
upper	NULL
band	NULL
migrated	NULL
with	NULL
the	NULL
same	NULL
mobility	NULL
as	NULL
the	NULL
retarded	NULL
bands	NULL
seen	NULL
with	NULL
a	NULL
labeled	NULL
(	NULL
Ig	NULL
)	NULL
k	NULL
enhancer	NULL
Â«	NULL
B	NULL
probe	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
and	NULL
fainter	NULL
band	NULL
appeared	NULL
variably	NULL
and	NULL
may	NULL
result	NULL
from	NULL
proteolytic	NULL
degradation	NULL
of	NULL
the	NULL
upper	NULL
band	NULL
.	NULL

The	NULL
binding	NULL
was	NULL
competed	NULL
by	NULL
unlabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
labeled	NULL
IL-2	NULL
Â«	NULL
B	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
b	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
``	NULL
self	NULL
``	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
Ig	NULL
Â«	NULL
B	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
b	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Ig	NULL
Â«	NULL
B	NULL
oligonucleotides	NULL
containing	NULL
mutations	NULL
in	NULL
the	NULL
5	NULL
invariant	NULL
GGG	NULL
(	NULL
similar	NULL
to	NULL
the	NULL
M1	NULL
mutation	NULL
in	NULL
IL-2	NULL
Â«	NULL
B	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
``	NULL
5	NULL
'	NULL
Mut	NULL
``	NULL
)	NULL
or	NULL
in	NULL
the	NULL
3	NULL
'	NULL
TTCC	NULL
(	NULL
similar	NULL
to	NULL
the	NULL
M4	NULL
mutation	NULL
in	NULL
IL-2	NULL
Â«	NULL
B	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
,	NULL
``	NULL
3	NULL
'	NULL
Mut	NULL
``	NULL
)	NULL
failed	NULL
to	NULL
compete	NULL
for	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
5	NULL
)	NULL
.	NULL

The	NULL
factor	NULL
therefore	NULL
,	NULL
behaved	NULL
as	NULL
predicted	NULL
for	NULL
authentic	NULL
NF-KB	NULL
(	NULL
13	NULL
,	NULL
42	NULL
)	NULL
.	NULL

The	NULL
discrepancy	NULL
between	NULL
the	NULL
binding	NULL
seen	NULL
in	NULL
the	NULL
gel-shift	NULL
experiments	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
effect	NULL
in	NULL
transfection	NULL
assays	NULL
emphasizes	NULL
the	NULL
importance	NULL
of	NULL
corroborating	NULL
in	NULL
vitro	NULL
binding	NULL
analyses	NULL
with	NULL
experiments	NULL
performed	NULL
in	NULL
vivo	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
Downstream	NULL
APA	NULL
Site	NULL
Abrogate	NULL
IL-2	NULL
Promoter	NULL
Induction	NULL
.	NULL

-	NULL
We	NULL
also	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
both	NULL
AP-1	NULL
sites	NULL
in	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Two	NULL
AP-1	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
by	NULL
deletion	NULL
and	NULL
footprinting	NULL
analysis	NULL
at	NULL
~150	NULL
and	NULL
-180	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
12	NULL
,	NULL
14	NULL
,	NULL
15	NULL
,	NULL
30	NULL
)	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
a	NULL
and	NULL
3	NULL
a	NULL
)	NULL
.	NULL

The	NULL
upstream	NULL
AP-1	NULL
site	NULL
at	NULL
-180	NULL
bp	NULL
is	NULL
not	NULL
detected	NULL
by	NULL
footprinting	NULL
of	NULL
EL-4	NULL
nuclear	NULL
extracts	NULL
859	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
,	NULL
and	NULL
deletion	NULL
of	NULL
the	NULL
site	NULL
does	NULL
not	NULL
affect	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
JURK	NULL
AT	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
site	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
synergistic	NULL
response	NULL
to	NULL
IL-1	NULL
of	NULL
LBRM-33	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
downstream	NULL
AP-1	NULL
site	NULL
at	NULL
-150	NULL
bp	NULL
decreases	NULL
induction	NULL
to	NULL
11	NULL
%	NULL
of	NULL
the	NULL
wild-type	NULL
level	NULL
in	NULL
JURKAT	NULL
cells	NULL
,	NULL
and	NULL
to	NULL
27	NULL
%	NULL
of	NULL
the	NULL
wild-type	NULL
level	NULL
in	NULL
EL-4	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
14	NULL
)	NULL
.	NULL

This	NULL
site	NULL
binds	NULL
inducible	NULL
nuclear	NULL
proteins	NULL
from	NULL
EI	NULL
;	NULL
4	NULL
cells	NULL
,	NULL
and	NULL
has	NULL
a	NULL
higher	NULL
affinity	NULL
for	NULL
purified	NULL
AP-1	NULL
proteins	NULL
than	NULL
the	NULL
-180	NULL
bp	NULL
site	NULL
(	NULL
14	NULL
)	NULL
.	NULL

We	NULL
made	NULL
site-specific	NULL
mutations	NULL
in	NULL
both	NULL
AP-1	NULL
sites	NULL
and	NULL
transfected	NULL
the	NULL
mutants	NULL
into	NULL
Ar-5	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Both	NULL
mutations	NULL
in	NULL
the	NULL
downstream	NULL
(	NULL
-150	NULL
bp	NULL
)	NULL
AP-1	NULL
site	NULL
significantly	NULL
decreased	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
transfection	NULL
experiments	NULL
.	NULL

Mutant	NULL
M3	NULL
,	NULL
bearing	NULL
a	NULL
triple	NULL
base	NULL
mutation	NULL
(	NULL
AAA	NULL
to	NULL
CTC	NULL
)	NULL
showed	NULL
a	NULL
~95	NULL
%	NULL
decrease	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
crosslinked	NULL
anti-CD3e	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
a	NULL
,	NULL
bottom	NULL
)	NULL
,	NULL
and	NULL
a	NULL
60-80	NULL
%	NULL
decrease	NULL
in	NULL
response	NULL
to	NULL
TA3	NULL
cells	NULL
and	NULL
anti-CD3e	NULL
or	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

If	NULL
normalized	NULL
with	NULL
respect	NULL
to	NULL
wild-type	NULL
plasmid	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
induction	NULL
of	NULL
the	NULL
mutant	NULL
M3	NULL
promoter	NULL
would	NULL
be	NULL
decreased	NULL
by	NULL
two	NULL
to	NULL
threefold	NULL
further	NULL
(	NULL
see	NULL
normalized	NULL
hGH	NULL
values	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Mutant	NULL
M4	NULL
,	NULL
which	NULL
also	NULL
bears	NULL
a	NULL
triple	NULL
mutation	NULL
(	NULL
AGT	NULL
to	NULL
CAA	NULL
)	NULL
showed	NULL
no	NULL
response	NULL
at	NULL
all	NULL
to	NULL
any	NULL
stimulus	NULL
tested	NULL
(	NULL
>	NULL
95	NULL
%	NULL
decrease	NULL
,	NULL
Fig	NULL
.	NULL

3	NULL
a	NULL
,	NULL
bottom	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
although	NULL
the	NULL
plasmid	NULL
was	NULL
transfected	NULL
better	NULL
than	NULL
the	NULL
wild-type	NULL
.	NULL

In	NULL
contrast	NULL
the	NULL
M1	NULL
and	NULL
M2	NULL
mutations	NULL
in	NULL
the	NULL
upstream	NULL
AP-1	NULL
site	NULL
only	NULL
partly	NULL
decreased	NULL
induction	NULL
in	NULL
response	NULL
to	NULL
these	NULL
various	NULL
stimuli	NULL
(	NULL
25-65	NULL
%	NULL
decrease	NULL
,	NULL
Fig	NULL
.	NULL

3	NULL
a	NULL
,	NULL
bottom	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
downstream	NULL
AP-1	NULL
site	NULL
is	NULL
absolutely	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
stimuli	NULL
.	NULL

The	NULL
upstream	NULL
site	NULL
,	NULL
although	NULL
not	NULL
critical	NULL
,	NULL
may	NULL
enhance	NULL
activation	NULL
in	NULL
vivo	NULL
.	NULL

Our	NULL
mutations	NULL
monitor	NULL
the	NULL
AP-1	NULL
site	NULL
at	NULL
-150	NULL
bp	NULL
rather	NULL
than	NULL
the	NULL
CD28-responsive	NULL
site	NULL
that	NULL
is	NULL
located	NULL
immediately	NULL
upstream	NULL
(	NULL
19	NULL
)	NULL
,	NULL
since	NULL
they	NULL
abrogate	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
crosslinked	NULL
anti-CD3	NULL
in	NULL
the	NULL
complete	NULL
absence	NULL
of	NULL
accessory	NULL
cells	NULL
that	NULL
might	NULL
express	NULL
ligands	NULL
for	NULL
CD28	NULL
.	NULL

We	NULL
performed	NULL
gel-shift	NULL
assays	NULL
to	NULL
determine	NULL
if	NULL
either	NULL
AP-1	NULL
site	NULL
was	NULL
capable	NULL
of	NULL
binding	NULL
in	NULL
a	NULL
PKC-sensitive	NULL
manner	NULL
to	NULL
inducible	NULL
nuclear	NULL
factors	NULL
in	NULL
vitro	NULL
.	NULL

Radiolabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
either	NULL
AP-1	NULL
site	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
Ar-5	NULL
cells	NULL
.	NULL

The	NULL
-180	NULL
AP-1	NULL
site	NULL
probe	NULL
failed	NULL
to	NULL
bind	NULL
any	NULL
strongly	NULL
inducible	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
in	NULL
contrast	NULL
to	NULL
those	NULL
reported	NULL
for	NULL
LBRM	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
may	NULL
reflect	NULL
the	NULL
inability	NULL
of	NULL
H1	NULL
to	NULL
enhance	NULL
IL-2	NULL
gene	NULL
induction	NULL
in	NULL
Ar-5	NULL
cells	NULL
(	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
bound	NULL
to	NULL
a	NULL
nuclear	NULL
factor	NULL
found	NULL
only	NULL
in	NULL
activated	NULL
Ar-5	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
b	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
;	NULL
an	NULL
inducible	NULL
factor	NULL
of	NULL
identical	NULL
mobility	NULL
bound	NULL
to	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
metallothionein	NULL
AP-1	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
b	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
factor	NULL
was	NULL
identified	NULL
as	NULL
Fos	NULL
or	NULL
a	NULL
Fos-related	NULL
protein	NULL
(	NULL
30	NULL
)	NULL
.	NULL

It	NULL
was	NULL
detectable	NULL
at	NULL
30	NULL
min	NULL
after	NULL
activation	NULL
and	NULL
was	NULL
maximally	NULL
induced	NULL
at	NULL
1-2	NULL
h	NULL
,	NULL
as	NULL
expected	NULL
if	NULL
the	NULL
rapidly	NULL
inducible	NULL
Fos	NULL
family	NULL
members	NULL
were	NULL
involved	NULL
.	NULL

Its	NULL
migration	NULL
was	NULL
altered	NULL
by	NULL
affinity-purified	NULL
anti	NULL
44x	NULL
6	NULL
C	NULL
5	NULL
}	NULL
6	NULL
5	NULL
I	NULL
&	NULL
4	NULL
}	NULL
B	NULL
O	NULL
]	NULL
e	NULL
3	NULL
)	NULL
CG	NULL
4	NULL
&	NULL
2	NULL
}	NULL
1	NULL
S	NULL
Imon	NULL
ous	NULL
controls	NULL
c-fos	NULL
c-jun	NULL
c-fos	NULL
+	NULL
c-jun	NULL
plasmids	NULL
2	NULL
)	NULL
medium	NULL
soluble	NULL
aCD3	NULL
BJ	NULL
xtinked	NULL
aCD3	NULL
Figure	NULL
4	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
augmented	NULL
by	NULL
expression	NULL
of	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
.	NULL

Ar-5	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
2.5	NULL
ug	NULL
of	NULL
the	NULL
human	NULL
5	NULL
'	NULL
IL-2-CAT	NULL
plasmid	NULL
and	NULL
2.5	NULL
pg	NULL
each	NULL
of	NULL
the	NULL
human	NULL
c-Fos	NULL
,	NULL
c-Jun	NULL
,	NULL
or	NULL
control	NULL
expression	NULL
plasmids	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
1	NULL
%	NULL
anti-CD3	NULL
,	NULL
either	NULL
soluble	NULL
(	NULL
hatched	NULL
bars	NULL
)	NULL
,	NULL
or	NULL
crosslinked	NULL
with	NULL
immobilized	NULL
second	NULL
antibody	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
,	NULL
of	NULL
three	NULL
similar	NULL
ones	NULL
,	NULL
is	NULL
shown	NULL
.	NULL

bodies	NULL
to	NULL
the	NULL
Fos	NULL
M	NULL
peptide	NULL
(	NULL
51	NULL
)	NULL
that	NULL
were	NULL
capable	NULL
of	NULL
im-munoprecipitating	NULL
c-Fos	NULL
and	NULL
related	NULL
proteins	NULL
.	NULL

Its	NULL
binding	NULL
was	NULL
competed	NULL
by	NULL
unlabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
downstream	NULL
AP-1	NULL
site	NULL
or	NULL
the	NULL
metallothionein	NULL
AP-1	NULL
site	NULL
,	NULL
but	NULL
not	NULL
by	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
IL-2	NULL
Â«	NULL
B	NULL
site	NULL
or	NULL
the	NULL
M1	NULL
,	NULL
M2	NULL
,	NULL
M3	NULL
,	NULL
or	NULL
M4	NULL
mutations	NULL
in	NULL
the	NULL
AP-1	NULL
sites	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
AP-1	NULL
factor	NULL
in	NULL
Ar-5	NULL
cells	NULL
was	NULL
sensitive	NULL
to	NULL
PKC	NULL
depletion	NULL
by	NULL
chronic	NULL
phorbol	NULL
ester	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
b	NULL
;	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
with	NULL
6	NULL
and	NULL
8	NULL
)	NULL
,	NULL
although	NULL
there	NULL
was	NULL
no	NULL
effect	NULL
on	NULL
induction	NULL
of	NULL
NFAT-1	NULL
in	NULL
the	NULL
same	NULL
experiment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
6	NULL
,	NULL
lanes	NULL
9-12	NULL
)	NULL
.	NULL

Cotransfection	NULL
with	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
Expression	NULL
Plasmids	NULL
Increases	NULL
IL-2	NULL
Promoter	NULL
Induction	NULL
.	NULL

_	NULL
Fos-Jun	NULL
complexes	NULL
are	NULL
induced	NULL
after	NULL
TCR/CD3-mediated	NULL
activation	NULL
(	NULL
16	NULL
,	NULL
20	NULL
)	NULL
and	NULL
bind	NULL
to	NULL
AP-1	NULL
sites	NULL
in	NULL
vitro	NULL
(	NULL
7	NULL
)	NULL
.	NULL

We	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
expression	NULL
plasmids	NULL
to	NULL
enhance	NULL
the	NULL
induction	NULL
of	NULL
IL-	NULL
2-CAT	NULL
activity	NULL
in	NULL
transient	NULL
cotransfections	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

As	NULL
high	NULL
concentrations	NULL
of	NULL
plasmid	NULL
DNA	NULL
(	NULL
>	NULL
10	NULL
pug	NULL
)	NULL
inhibit	NULL
transfection	NULL
efficiency	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
IL-2-CAT	NULL
plasmid	NULL
transfected	NULL
was	NULL
decreased	NULL
by	NULL
the	NULL
amount	NULL
of	NULL
c-Fos	NULL
,	NULL
c-Jun	NULL
,	NULL
or	NULL
con	NULL
trol	NULL
plasmids	NULL
used	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
the	NULL
IL2-CAT	NULL
plasmid	NULL
cotransfected	NULL
with	NULL
control	NULL
plasmids	NULL
for	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
was	NULL
weakly	NULL
induced	NULL
by	NULL
crosslinked	NULL
anti-CD3Â¢	NULL
(	NULL
4.3-fold	NULL
in	NULL
this	NULL
experiment	NULL
)	NULL
,	NULL
presumably	NULL
because	NULL
the	NULL
FBJ-MSV	NULL
and	NULL
RSV	NULL
LTRs	NULL
present	NULL
in	NULL
the	NULL
control	NULL
plasmids	NULL
competed	NULL
for	NULL
binding	NULL
of	NULL
transcription	NULL
factors	NULL
also	NULL
required	NULL
for	NULL
IL-2	NULL
promoter	NULL
induction	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
}	NULL
.	NULL

Cotransfection	NULL
of	NULL
either	NULL
c-Fos	NULL
or	NULL
c-Jun	NULL
with	NULL
IL-2-CAT	NULL
resulted	NULL
in	NULL
increased	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
stimulated	NULL
T	NULL
cells	NULL
(	NULL
to	NULL
27-fold	NULL
and	NULL
13-fold	NULL
,	NULL
respectively	NULL
;	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Cotransfection	NULL
of	NULL
both	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
with	NULL
IL-2-CAT	NULL
resulted	NULL
in	NULL
a	NULL
44-fold	NULL
induction	NULL
of	NULL
IL-2-CAT	NULL
.	NULL

This	NULL
represents	NULL
a	NULL
10-fold	NULL
enhancement	NULL
over	NULL
the	NULL
control	NULL
cotransfection	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cotransfection	NULL
of	NULL
either	NULL
c-Fos	NULL
alone	NULL
,	NULL
or	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
together	NULL
uncovered	NULL
a	NULL
threefold	NULL
induction	NULL
of	NULL
IL-2-CAT	NULL
by	NULL
soluble	NULL
anti-CD3e	NULL
,	NULL
which	NULL
alone	NULL
was	NULL
insufficient	NULL
to	NULL
induce	NULL
IL-2-CAT	NULL
expression	NULL
.	NULL

Cotransfection	NULL
of	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
,	NULL
either	NULL
individually	NULL
or	NULL
together	NULL
,	NULL
did	NULL
not	NULL
cause	NULL
induction	NULL
of	NULL
II-2-CAT	NULL
activity	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
,	NULL
confirming	NULL
that	NULL
other	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
NFAT-1	NULL
are	NULL
also	NULL
required	NULL
for	NULL
induction	NULL
.	NULL

Cotransfection	NULL
with	NULL
c-Fos	NULL
alone	NULL
causes	NULL
a	NULL
reproducible	NULL
three-	NULL
to	NULL
fivefold	NULL
increase	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
IL-2-CAT	NULL
activity	NULL
in	NULL
stimulated	NULL
T	NULL
cells	NULL
,	NULL
possibly	NULL
because	NULL
induction	NULL
of	NULL
c-Jun	NULL
(	NULL
which	NULL
is	NULL
expressed	NULL
in	NULL
resting	NULL
cells	NULL
)	NULL
is	NULL
not	NULL
limiting	NULL
for	NULL
AP-1	NULL
activity	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cotransfection	NULL
with	NULL
c-Jun	NULL
alone	NULL
has	NULL
a	NULL
more	NULL
variable	NULL
effect	NULL
,	NULL
indicating	NULL
that	NULL
induction	NULL
of	NULL
c-Fos	NULL
or	NULL
other	NULL
Fos	NULL
family	NULL
members	NULL
may	NULL
be	NULL
limiting	NULL
.	NULL

Cotransfection	NULL
with	NULL
c-Fos	NULL
did	NULL
not	NULL
increase	NULL
induction	NULL
of	NULL
the	NULL
AP-1	NULL
site	NULL
mutants	NULL
M3	NULL
and	NULL
M4	NULL
in	NULL
response	NULL
to	NULL
crosslinked	NULL
anti-CD3e	NULL
(	NULL
30	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
possibility	NULL
that	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
act	NULL
to	NULL
enhance	NULL
IL-2-CAT	NULL
induction	NULL
by	NULL
binding	NULL
to	NULL
the	NULL
-150	NULL
bp	NULL
AP-1	NULL
site	NULL
,	NULL
and	NULL
provide	NULL
further	NULL
in	NULL
vivo	NULL
evidence	NULL
for	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
for	NULL
IL-2	NULL
promoter	NULL
activation	NULL
in	NULL
untransformed	NULL
T	NULL
cells	NULL
.	NULL

Conclusions	NULL
.	NULL

-	NULL
In	NULL
summary	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
IL-2	NULL
NF-KB	NULL
site	NULL
is	NULL
not	NULL
required	NULL
for	NULL
TCR-mediated	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
an	NULL
untransformed	NULL
T	NULL
cell	NULL
clone	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
AP-1	NULL
site	NULL
at	NULL
-150	NULL
is	NULL
clearly	NULL
required	NULL
for	NULL
induction	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
inducible	NULL
binding	NULL
with	NULL
the	NULL
-180	NULL
AP-1	NULL
site	NULL
in	NULL
gel-shift	NULL
assays	NULL
,	NULL
our	NULL
results	NULL
establish	NULL
that	NULL
the	NULL
-150	NULL
AP-1	NULL
site	NULL
is	NULL
a	NULL
major	NULL
,	NULL
if	NULL
not	NULL
the	NULL
only	NULL
,	NULL
kinase	NULL
C-responsive	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Cotransfection	NULL
with	NULL
c-fos	NULL
and	NULL
c-jun	NULL
expression	NULL
plasmids	NULL
enhances	NULL
IL-2	NULL
promoter	NULL
induction	NULL
,	NULL
most	NULL
likely	NULL
by	NULL
acting	NULL
at	NULL
the	NULL
AP-1	NULL
site	NULL
at	NULL
-150	NULL
bp	NULL
.	NULL

However	NULL
,	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
established	NULL
which	NULL
of	NULL
the	NULL
various	NULL
Fos/Jun	NULL
family	NULL
members	NULL
actually	NULL
mediate	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
thank	NULL
E.	NULL
Serfling	NULL
for	NULL
the	NULL
murine	NULL
5Â°	NULL
IL2-CAT	NULL
plasmids	NULL
and	NULL
for	NULL
many	NULL
helpful	NULL
comments	NULL
;	NULL
R.	NULL
Distel	NULL
for	NULL
the	NULL
metallothionein	NULL
AP-1	NULL
site	NULL
oligonucleotide	NULL
;	NULL
M.	NULL
Siekevitz	NULL
for	NULL
the	NULL
IL2	NULL
Â«	NULL
B	NULL
site	NULL
mutants	NULL
;	NULL
I.	NULL
Verma	NULL
for	NULL
the	NULL
human	NULL
c-Fos	NULL
expression	NULL
plasmid	NULL
BK28	NULL
;	NULL
and	NULL
M.	NULL
Karin	NULL
for	NULL
the	NULL
human	NULL
c-Jun	NULL
expression	NULL
plasmid	NULL
pRSV-cJ	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grant	NULL
CA-42471	NULL
to	NULL
A.	NULL
Rao	NULL
.	NULL

J.	NULL
Jain	NULL
was	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
postdoctoral	NULL
fellowship	NULL
from	NULL
the	NULL
Lady	NULL
Tata	NULL
Memorial	NULL
Trust	NULL
.	NULL

V.	NULL
Valge-Archer	NULL
was	NULL
supported	NULL
by	NULL
U.S.	NULL
Department	NULL
of	NULL
Agriculture	NULL
training	NULL
grant	NULL
in	NULL
Biotechnology	NULL
Â§4-GRAD-9-0018	NULL
.	NULL

A.	NULL
Sinskey	NULL
was	NULL
860	NULL
AP-1	NULL
and	NULL
NFkB	NULL
Sites	NULL
in	NULL
the	NULL
Interleukin	NULL
2	NULL
Promoter	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Massachusetts	NULL
Institute	NULL
of	NULL
Technology	NULL
Biotechnology	NULL
Process	NULL
Engineering	NULL
Center	NULL
,	NULL
National	NULL
Science	NULL
Foundation	NULL
Engineering	NULL
Research	NULL
Center	NULL
Initiative	NULL
Cooperative	NULL
Agreement	NULL
CPR-00003	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Anjana	NULL
Rao	NULL
,	NULL
Mayer	NULL
Building	NULL
,	NULL
Room	NULL
613	NULL
,	NULL
Division	NULL
of	NULL
Tumour	NULL
Virology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
44	NULL
Binney	NULL
Street	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Viia	NULL
E.	NULL
Valge-Archer	NULL
's	NULL
current	NULL
address	NULL
is	NULL
:	NULL
Protein	NULL
and	NULL
Nucleic	NULL
Acid	NULL
Chemistry	NULL
Division	NULL
,	NULL
MRC	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Biology	NULL
,	NULL
Cambridge	NULL
CB2	NULL
2QH	NULL
England	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
22	NULL
August	NULL
1991	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
11	NULL
November	NULL
1991	NULL
.	NULL

References	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

Klausner	NULL
,	NULL
R.D	NULL
.	NULL

,	NULL
and	NULL
L.E	NULL
.	NULL

Samelson	NULL
.	NULL

1991	NULL
.	NULL

T	NULL
cell	NULL
antigen	NULL
receptor	NULL
activation	NULL
pathways	NULL
:	NULL
the	NULL
tyrosine	NULL
kinase	NULL
connection	NULL
.	NULL

Cell	NULL
.	NULL

64:875.	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

1991	NULL
.	NULL

Signaling	NULL
mechanisms	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Im-	NULL
munol	NULL
.	NULL

10:495.	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
J.P.	NULL
Northrop	NULL
,	NULL
C.L	NULL
.	NULL

Verweij	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crab	NULL
tree	NULL
.	NULL

1990	NULL
.	NULL

Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
.	NULL

Ann	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:421.	NULL
.	NULL

Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

1986	NULL
.	NULL

Studies	NULL
and	NULL
perspectives	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

233:305.	NULL
.	NULL

Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
molecular	NULL
heterogeneity	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
its	NULL
implications	NULL
for	NULL
cellular	NULL
regulation	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

334:661.	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
J.B.	NULL
Imboden	NULL
.	NULL

1987	NULL
.	NULL

Cell	NULL
surface	NULL
molecules	NULL
and	NULL
early	NULL
events	NULL
involved	NULL
in	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Adu	NULL
.	NULL

Immunol	NULL
.	NULL

41:1.	NULL
.	NULL

Curran	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
BR	NULL
.	NULL

Franza	NULL
.	NULL

1988	NULL
.	NULL

Fos	NULL
and	NULL
Jun	NULL
:	NULL
The	NULL
AP-1	NULL
connection	NULL
.	NULL

Cell	NULL
.	NULL

55:395.	NULL
.	NULL

Boyle	NULL
,	NULL
WJ	NULL
.	NULL

,	NULL
T.	NULL
Smeal	NULL
,	NULL
LH.K	NULL
.	NULL

Defize	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
J.R.	NULL
Woodgett	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
T.	NULL
Hunter	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
decreases	NULL
phosphorylation	NULL
of	NULL
c-Jun	NULL
at	NULL
sites	NULL
that	NULL
negatively	NULL
regulate	NULL
its	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Cell	NULL
.	NULL

64:573.	NULL
.	NULL

Lenardo	NULL
,	NULL
M.J.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

NF-kB	NULL
:	NULL
A	NULL
pleiotropic	NULL
mediator	NULL
of	NULL
inducible	NULL
and	NULL
tissue-specific	NULL
gene	NULL
control	NULL
.	NULL

Cell	NULL
.	NULL

58:227	NULL
.	NULL

KriÃ©nke	NULL
,	NULL
M.	NULL
,	NULL
WJ	NULL
.	NULL

Leonard	NULL
,	NULL
J.M	NULL
.	NULL

Depper	NULL
,	NULL
and	NULL
W.C.	NULL
Greene	NULL
.	NULL

1985	NULL
.	NULL

Sequential	NULL
expression	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
human	NULL
T	NULL
lymphocyte	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

161:1593	NULL
.	NULL

Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
PJ	NULL
.	NULL

Utz	NULL
,	NULL
D.B	NULL
.	NULL

Durand	NULL
,	NULL
J.J.	NULL
Toole	NULL
,	NULL
E.A	NULL
.	NULL

Emmel	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

241:202	NULL
.	NULL

Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.R	NULL
.	NULL

Bush	NULL
,	NULL
R.E	NULL
.	NULL

Replogle	NULL
,	NULL
R.	NULL
Be-lagaje	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin	NULL
2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
DW	NULL
.	NULL

Ballard	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
M.	NULL
Siekevitz	NULL
,	NULL
and	NULL
W.C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Kappa	NULL
B-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
:	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
expression	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

244:457	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
R.	NULL
Barthelmas	NULL
,	NULL
I.	NULL
Pfeuffer	NULL
,	NULL
B.	NULL
Schenk	NULL
,	NULL
S.	NULL
Zarius	NULL
,	NULL
R.	NULL
Swoboda	NULL
,	NULL
F.	NULL
Mercurio	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Ubiquitous	NULL
and	NULL
lymphocyte-specific	NULL
factors	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
mouse	NULL
interleukin	NULL
2	NULL
gene	NULL
in	NULL
T	NULL
lymphocytes	NULL
,	NULL
EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

8:465	NULL
.	NULL

Randak	NULL
,	NULL
C.	NULL
,	NULL
T.	NULL
Brabletz	NULL
,	NULL
M.	NULL
Hergenrother	NULL
,	NULL
I.	NULL
Sobotta	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1990	NULL
.	NULL

Cyclosporin	NULL
A	NULL
suppresses	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
by	NULL
inhibiting	NULL
the	NULL
binding	NULL
of	NULL
lymphocyte	NULL
861	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28.	NULL
specific	NULL
factors	NULL
to	NULL
the	NULL
IL2	NULL
enhancer	NULL
,	NULL
EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
,	NULL
Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

9:2529	NULL
.	NULL

Muegge	NULL
,	NULL
K.	NULL
,	NULL
T.M	NULL
.	NULL

Williams	NULL
,	NULL
J.	NULL
Kant	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
U.	NULL
Siebenlist	NULL
,	NULL
H.A	NULL
.	NULL

Young	NULL
,	NULL
and	NULL
$	NULL
.K	NULL
.	NULL

Durum	NULL
.	NULL

1989	NULL
.	NULL

Interleukin-1	NULL
costimulatory	NULL
activity	NULL
on	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
via	NULL
AP-1	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

246:249	NULL
.	NULL

Kamps	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
L.	NULL
Corcoran	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
gene	NULL
contains	NULL
two	NULL
octamer-binding	NULL
sites	NULL
and	NULL
is	NULL
partially	NULL
activated	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
Oct-2	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:5464	NULL
.	NULL

Mattila	NULL
,	NULL
PS	NULL
.	NULL

,	NULL
K.S	NULL
.	NULL

Ullman	NULL
,	NULL
S.	NULL
Fiering	NULL
,	NULL
EA	NULL
.	NULL

Emmel	NULL
,	NULL
M.	NULL
McCutcheon	NULL
,	NULL
G.R	NULL
.	NULL

Crabtree	NULL
,	NULL
and	NULL
L.A.	NULL
Herzenberg	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
action	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
suggest	NULL
a	NULL
novel	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

94425	NULL
.	NULL

Fraser	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
B.A	NULL
.	NULL

Irving	NULL
,	NULL
G.R	NULL
.	NULL

Crabtree	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
interleukin-2	NULL
gene	NULL
enhancer	NULL
activity	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

251:313	NULL
.	NULL

Valge	NULL
,	NULL
V.E	NULL
.	NULL

,	NULL
J.G.P	NULL
.	NULL

Wong	NULL
,	NULL
B.M	NULL
.	NULL

Datlof	NULL
,	NULL
A.J	NULL
.	NULL

Sinskey	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1988	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
is	NULL
required	NULL
for	NULL
responses	NULL
to	NULL
T	NULL
cell	NULL
receptor	NULL
ligands	NULL
but	NULL
not	NULL
to	NULL
interleukin-2	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Cell	NULL
.	NULL

55:101	NULL
.	NULL

Berridge	NULL
,	NULL
M.J.	NULL
1987	NULL
.	NULL

Inositol	NULL
trisphosphate	NULL
and	NULL
diacylglycerol	NULL
:	NULL
two	NULL
interacting	NULL
second	NULL
messengers	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

56:159	NULL
.	NULL

Juszczak	NULL
,	NULL
R.J.	NULL
,	NULL
and	NULL
J.	NULL
H.	NULL
Russell	NULL
.	NULL

1989	NULL
.	NULL

Inhibition	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocyte-mediated	NULL
lysis	NULL
and	NULL
cellular	NULL
proliferation	NULL
by	NULL
iso-quinoline	NULL
sulfonamide	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
.	NULL

Evidence	NULL
for	NULL
the	NULL
involvement	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
in	NULL
lymphocyte	NULL
function	NULL
.	NULL

_J	NULL
.	NULL

Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:810	NULL
.	NULL

Rodriguez-Pena	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
E.	NULL
Rozengurt	NULL
.	NULL

1984	NULL
.	NULL

Disappearance	NULL
of	NULL
-sensitive	NULL
,	NULL
phospholipid-dependent	NULL
protein	NULL
kinase	NULL
activity	NULL
in	NULL
phorbol	NULL
ester-treated	NULL
3T	NULL
3	NULL
cells	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

120:1053	NULL
.	NULL

Ballester	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
O.	NULL
Rosen	NULL
.	NULL

1985	NULL
.	NULL

Rate	NULL
of	NULL
immunoprecipitable	NULL
protein	NULL
kinase	NULL
C	NULL
in	NULL
GH3	NULL
cells	NULL
treated	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-actetate	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

260:15194	NULL
.	NULL

Young	NULL
,	NULL
S.	NULL
,	NULL
P.J	NULL
.	NULL

Parker	NULL
,	NULL
A.	NULL
Ullrich	NULL
,	NULL
and	NULL
S.	NULL
Stabel	NULL
.	NULL

1987	NULL
.	NULL

Down-regulation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
is	NULL
due	NULL
to	NULL
an	NULL
increased	NULL
rate	NULL
of	NULL
degradation	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

244:775	NULL
.	NULL

Kim	NULL
,	NULL
D.	NULL
,	NULL
D.W.	NULL
Lancki	NULL
,	NULL
FEH	NULL
.	NULL

Hui	NULL
,	NULL
and	NULL
FW	NULL
.	NULL

Fitch	NULL
.	NULL

1989	NULL
.	NULL

Protein	NULL
kinase	NULL
C-dependent	NULL
and	NULL
-independent	NULL
mechanisms	NULL
of	NULL
cloned	NULL
murine	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:616	NULL
.	NULL

Strulovici	NULL
,	NULL
B.	NULL
,	NULL
S.	NULL
Daniel-Issakani	NULL
,	NULL
G.	NULL
Baxter	NULL
,	NULL
J.	NULL
Knopf	NULL
,	NULL
L.	NULL
Sultzman	NULL
,	NULL
H.	NULL
Cherwinski	NULL
,	NULL
J.	NULL
Nestor	NULL
,	NULL
D.R	NULL
.	NULL

Webb	NULL
,	NULL
and	NULL
J	NULL
.	NULL

Ransom	NULL
.	NULL

1991	NULL
.	NULL

Distinct	NULL
mechanisms	NULL
of	NULL
regulation	NULL
of	NULL
protein	NULL
kinase	NULL
Ce	NULL
by	NULL
hormones	NULL
and	NULL
phorbol	NULL
diesters	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:168	NULL
.	NULL

Krimpenfort	NULL
,	NULL
P.	NULL
,	NULL
R.	NULL
de	NULL
Jong	NULL
,	NULL
Y.	NULL
Uematsu	NULL
,	NULL
Z.	NULL
Dembic	NULL
,	NULL
S.	NULL
Ryser	NULL
,	NULL
H.	NULL
von	NULL
Boehmer	NULL
,	NULL
M.	NULL
Steinmetz	NULL
,	NULL
and	NULL
A.	NULL
Berns	NULL
.	NULL

1988	NULL
.	NULL

Transcription	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
B-chain	NULL
genes	NULL
is	NULL
controlled	NULL
by	NULL
a	NULL
29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40.	NULL
downstream	NULL
regulatory	NULL
element	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

7:745	NULL
.	NULL

Rao	NULL
,	NULL
A.	NULL
,	NULL
S.J	NULL
.	NULL

Faas	NULL
,	NULL
and	NULL
H.	NULL
Cantor	NULL
.	NULL

1984	NULL
.	NULL

Activation	NULL
specificity	NULL
of	NULL
arsonate-reactive	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

Structural	NULL
requirements	NULL
for	NULL
hapten	NULL
recognition	NULL
and	NULL
comparison	NULL
with	NULL
monoclonal	NULL
anti-bodies	NULL
.	NULL

J.	NULL
Exp	NULL
Med	NULL
.	NULL

159:479	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
V.E	NULL
.	NULL

Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

accepted	NULL
for	NULL
publi-cation	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
D.B	NULL
.	NULL

Durand	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
N.K	NULL
.	NULL

Holbrook	NULL
,	NULL
C.	NULL
A.	NULL
Norris	NULL
,	NULL
M.	NULL
Kamoun	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kant	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1986	NULL
.	NULL

Promoter	NULL
region	NULL
of	NULL
interleukin-2	NULL
gene	NULL
undergoes	NULL
chromatin	NULL
structure	NULL
changes	NULL
and	NULL
confers	NULL
inducibility	NULL
on	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:3042	NULL
.	NULL

Kunkel	NULL
,	NULL
T.A	NULL
.	NULL

1985	NULL
.	NULL

Rapid	NULL
and	NULL
efficient	NULL
site-specific	NULL
mutagenesis	NULL
without	NULL
phenotypic	NULL
selection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

82:488	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

Sassone-Corsi	NULL
,	NULL
P.	NULL
,	NULL
J.C.	NULL
Sisson	NULL
,	NULL
and	NULL
I.M	NULL
.	NULL

Verma	NULL
.	NULL

1988	NULL
.	NULL

Transcriptional	NULL
autoregulation	NULL
of	NULL
the	NULL
proto-oncogene	NULL
fos	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

334:314	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
Hattori	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
jun	NULL
proto-oncogene	NULL
is	NULL
positively	NULL
autoregulated	NULL
by	NULL
its	NULL
product	NULL
,	NULL
Jun/AP-1	NULL
.	NULL

Cell	NULL
.	NULL

55:875	NULL
.	NULL

Wong	NULL
,	NULL
J.G.P	NULL
.	NULL

,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1990	NULL
.	NULL

Mutants	NULL
in	NULL
signal	NULL
transduction	NULL
through	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

J.	NULL
Biol	NULL
Chem	NULL
.	NULL

265:4685	NULL
.	NULL

Gorman	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
GT	NULL
.	NULL

Merlino	NULL
,	NULL
M.C	NULL
.	NULL

Willingham	NULL
,	NULL
I.	NULL
Pastan	NULL
,	NULL
and	NULL
B.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

The	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
is	NULL
a	NULL
strong	NULL
promoter	NULL
when	NULL
introduced	NULL
into	NULL
a	NULL
variety	NULL
of	NULL
eukaryotic	NULL
cells	NULL
by	NULL
DNA	NULL
mediated	NULL
transfection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

79:6777	NULL
.	NULL

Bradford	NULL
,	NULL
M.	NULL
1976	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quan-titation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
binding	NULL
.	NULL

Anal	NULL
.	NULL

Biockem	NULL
.	NULL

72:248	NULL
.	NULL

Luckow	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
G.	NULL
Schultz	NULL
.	NULL

1987	NULL
.	NULL

CAT	NULL
constructions	NULL
with	NULL
multiple	NULL
unique	NULL
restriction	NULL
sites	NULL
for	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
eukaryotic	NULL
promoters	NULL
and	NULL
regulatory	NULL
elements	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15:5490	NULL
.	NULL

Leo	NULL
,	NULL
O.	NULL
,	NULL
M.	NULL
Foo	NULL
,	NULL
D.H.	NULL
Sachs	NULL
,	NULL
LE	NULL
.	NULL

Samelson	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Blue-stone	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
monoclonal	NULL
antibody	NULL
specific	NULL
862	NULL
41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51.	NULL
for	NULL
a	NULL
murine	NULL
T3	NULL
polypeptide	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:1374	NULL
.	NULL

Sakurai	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
J.L	NULL
.	NULL

Strominger	NULL
.	NULL

1988	NULL
.	NULL

B-cell-specific	NULL
enhancer	NULL
activity	NULL
of	NULL
conserved	NULL
upstream	NULL
elements	NULL
of	NULL
the	NULL
class	NULL
II	NULL
major	NULL
histocompatibility	NULL
complex	NULL
DQB	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

85:6909	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
.	NULL

46:705	NULL
.	NULL

Rauscher	NULL
,	NULL
FJ	NULL
.	NULL

III	NULL
,	NULL
L.C	NULL
.	NULL

Sambucetti	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
R.J.	NULL
Distel	NULL
,	NULL
and	NULL
B.M	NULL
.	NULL

Spiegelman	NULL
.	NULL

1988	NULL
.	NULL

Common	NULL
DNA	NULL
binding	NULL
site	NULL
for	NULL
Fos	NULL
protein	NULL
complexes	NULL
and	NULL
transcription	NULL
factor	NULL
AP-1	NULL
.	NULL

Cell	NULL
.	NULL

52:471	NULL
.	NULL

Dignam	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
R.M	NULL
.	NULL

Lebovitz	NULL
,	NULL
and	NULL
RG	NULL
.	NULL

Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475	NULL
.	NULL

Verweij	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
C.	NULL
Guidos	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1990	NULL
.	NULL

Cell	NULL
type	NULL
specificity	NULL
and	NULL
activation	NULL
requirements	NULL
for	NULL
NFAT-1	NULL
(	NULL
Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T-cells	NULL
)	NULL
transcriptional	NULL
activity	NULL
determined	NULL
by	NULL
a	NULL
new	NULL
method	NULL
using	NULL
transgenic	NULL
mice	NULL
to	NULL
assay	NULL
transcriptional	NULL
activity	NULL
of	NULL
an	NULL
individual	NULL
nuclear	NULL
factor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:15788	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Activation	NULL
in	NULL
vitro	NULL
of	NULL
NFkB	NULL
by	NULL
phosphorylation	NULL
of	NULL
its	NULL
inhibitor	NULL
IxB	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

344:678	NULL
.	NULL

Radler-Pohl	NULL
,	NULL
A.	NULL
,	NULL
I.	NULL
Pfeuffer	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
novel	NULL
T-cell	NULL
trans-activator	NULL
that	NULL
recognizes	NULL
a	NULL
phorbol	NULL
ester-inducible	NULL
element	NULL
for	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
.	NULL

The	NULL
New	NULL
Bi-ologist	NULL
.	NULL

2:566	NULL
.	NULL

Emmel	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
C.L	NULL
.	NULL

Verweij	NULL
,	NULL
D.B	NULL
.	NULL

Durand	NULL
,	NULL
K.M	NULL
.	NULL

Higgins	NULL
,	NULL
E.	NULL
Lacy	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A	NULL
specifically	NULL
inhibits	NULL
function	NULL
of	NULL
nuclear	NULL
proteins	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

246:1617	NULL
.	NULL

Zabel	NULL
,	NULL
U.	NULL
,	NULL
R.	NULL
Schreck	NULL
,	NULL
and	NULL
P.A	NULL
.	NULL

Baeuerle	NULL
.	NULL

1991	NULL
.	NULL

DNA	NULL
binding	NULL
of	NULL
purified	NULL
transcription	NULL
factor	NULL
NF-	NULL
Â«	NULL
B	NULL
:	NULL
Affinity	NULL
,	NULL
specificity	NULL
,	NULL
Zn**	NULL
dependence	NULL
,	NULL
and	NULL
differential	NULL
half-site	NULL
recognition	NULL
.	NULL

J.	NULL
Bio/	NULL
.	NULL

Chem	NULL
.	NULL

266:252	NULL
.	NULL

Urban	NULL
,	NULL
M.B	NULL
.	NULL

,	NULL
and	NULL
P.A	NULL
.	NULL

Baeuerle	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
65-	NULL
Â«	NULL
D	NULL
subunit	NULL
of	NULL
NF-KB	NULL
is	NULL
a	NULL
receptor	NULL
for	NULL
IxB	NULL
and	NULL
a	NULL
modulator	NULL
of	NULL
DNA-binding	NULL
specificity	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
,	NULL
4:1975	NULL
.	NULL

Curran	NULL
,	NULL
T.	NULL
,	NULL
CV	NULL
.	NULL

Beveren	NULL
,	NULL
N.	NULL
Ling	NULL
,	NULL
and	NULL
LM	NULL
.	NULL

Verma	NULL
.	NULL

1985	NULL
.	NULL

Viral	NULL
and	NULL
cellular	NULL
fos	NULL
proteins	NULL
are	NULL
complexed	NULL
with	NULL
a	NULL
39,000-dalton	NULL
cellular	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5:167	NULL
.	NULL

AP-1	NULL
and	NULL
Sites	NULL
in	NULL
the	NULL
Interleukin	NULL
2	NULL
Promoter	NULL

